

Table of Contents

Cross portfolio Community Health and Hospitals Program Grants.....	page 2
Program 1.1_Patients Funding Agreements.....	page 8
Program 1.1_MRFF 10 Year investment plan - budget committed and not yet committed funding.....	page 14
Program 1.1_MRFF 10 year investment plan - breakdown of committed allocated and not yet allocated.....	page 22
Program 1.1_MRFF Funding Agreements in progress not yet executed.....	page 23
Program 1.1_MRFF Missions Funding Agreements.....	page 24
Program 1.1_MRFF Researches Funding Agreements.....	page 26
Program 1.1_MRFF Translation Funding Agreements.....	page 34
Program 1.2_ Health Innovation and Technology_My Health Record.....	page 39
Program 4.1_Medical Benefits GP Bulk Billing.....	page 40
Program 4.3_Pharmaceutical Benefits PBAC.....	page 45

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
Western Australia	City of Albany Youth Hub	Program 2.1	0.300							0.300	Executed
	Outside the Locker Room	Program 2.1	0.350	0.350	0.350	0.350	0.350			1.750	Executed
	Breaking the Silence - Regional WA Domestic Violence Program - 10 sites	Program 2.1		0.650	0.835	0.841				2.326	Executed
	Primary care-led multidisciplinary care for Chronic Heart Failure	Program 2.4					0.800	1.500	1.500	3.800	In Progress
	Expansion of the Choices service – reducing the treatment gap and failure to engage with care for high frequency Mental Health and Alcohol & Other Drug service users	Program 2.1		1.127	1.856	2.258				5.241	In Progress
	Primary healthcare hubs - enhancing primary care-led mental health and drug and alcohol support services	Program 2.1		1.050	1.915	1.800				4.765	In Progress
	Goldfields Rehabilitation Services	Program 2.4		1.500						1.500	In Progress
	Supporting the infrastructure of Women and Newborn Health Service – King Edward Memorial Hospital	Treasury	3.200	3.500	3.500	5.000				15.200	In Progress
	Ellenbrook Mental Health Facility - provision of mental health and support services, mental health crisis facility at the St John of God Midland hospital	Treasury			1.500	1.500	2.000	1.000		6.000	In Progress
	Peel Hospital Campus to expand and refurbish the existing Emergency Department, relocate and fit out the Imaging Department and construct new Community mental Health facilities including a residential eating disorders centre	Treasury			7.500	7.500	10.000			25.000	In Progress
	WACHS Cancer Strategy Implementation and Greater Southern radiation oncology capital which aims to increase survival and improve the quality of life for country people diagnosed with cancer. WACHS will also develop infrastructure to enable the delivery of oncology treatment services within the southern region in Albany	Treasury				6.278	6.278	6.278	6.300	25.134	In Progress
	Laverton Community Hospital Replacement - new contemporary facility that will provide emergency, population health and ambulatory care services; promote primary health care and support the delivery of multidisciplinary services for the community of Laverton	Treasury					6.200	9.600	1.000	16.800	In Progress
	Youth Forensic Inpatient Service - provide a 10 bed youth forensic mental health ward in WA. The ward is to support forensic youth with mental health issues in a medium secure environment, where young people can be assessed and treated. Youth will be able to transition through the court system in safety	Treasury					7.800	7.000		14.800	In Progress
Comprehensive genomic testing - Specialists and equipment to establish genomic testing for the management of cancer patients and treatment in Western Australia. Matching treatments with the individual patient's cancer profile will provide patients which the best chances of survival	Treasury					9.500	9.500		19.000	In Progress	

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
Victoria	Monash University/Peninsula Health - Health Futures Hub	Program 1.1	0.800	1.600	3.800	8.400	17.400			32.000	Executed
	My Place Youth Centre	Program 2.1	1.500							1.500	Executed
	Peter Mac - Cellular Immunotherapy	Program 1.3	25.000		6.000	6.000	7.000	9.000	27.000	80.000	Executed
	BlueHub Project - Framework for Police and Emergency Services Mental Health	Program 2.1	2.500							2.500	Executed
	Youth Hub Lilydale	Program 2.1	1.500	1.500	1.500					4.500	Executed
	The Cottage - Shepparton	Program 2.4		0.100	0.100	0.100				0.300	Executed
	Community transport service for rural Victoria	Program 1.3				1.173	2.187	2.217		5.577	In Progress
	HALT suicide prevention community worker - North Western Melbourne PHN	Program 2.1		0.250	0.250	0.250	0.250			1.000	In Progress
	HALT suicide prevention community worker - South East Melbourne PHN	Program 2.1		0.250	0.250	0.250	0.250			1.000	In Progress
	Alfred Health and Monash University - Australian Clinical Trials Network 'TrialHub'	Program 1.1		3.000	3.000	3.000	5.200	5.200	5.200	24.600	In Progress
	Cabrini Institute of Cancer	Program 1.1			1.500	1.500	1.500	1.500		6.000	In Progress
	Aikenhead Centre for Medical Discovery to establish Australia's first hospital-based biomedical engineering research and training hub in Melbourne	Treasury	10.000			4.000	6.000	6.000	4.000	30.000	In Progress
	Establishment of an Eating Disorders Treatment Centre	Treasury	6.500				4.000	2.500		13.000	In Progress
	Goulburn Valley Hospital Cancer Centre - staged upgrade of infrastructure	Treasury					5.300	10.000	14.700	30.000	In Progress
Paediatric Emergency Departments for Geelong, Maroondah, Frankston & Casey emergency departments to ensure facilities are appropriate for families and children	Treasury					13.000	25.000	2.000	40.000	In Progress	
Geelong Women's and Children's Hospital (Barwon Health) - Upgrade the existing facilities to provide short term and immediate services for women and children (Stage 1) and construct a new facility accommodate acute and sub-acute women's and children's services (Stage 2)	Treasury					25.000	25.000		50.000	In Progress	
Tasmania	City Mission Drug Res Rehab	Program 2.4	3.100	0.460	0.920	0.920	0.920			6.320	Executed
	Mental Health/Alcohol and Drug Comorbidity Workers	Program 2.4	0.113	0.450	0.450	0.111				1.124	Executed
	Construction of a facility to enhance elective surgery	Treasury	5.000		5.000	5.000	5.000			20.000	In Progress
	Construction of a facility and purchase of a Linear Accelerator for the North West Regional Hospital	Treasury	4.400							4.400	In Progress
	Establishment of an Eating Disorders Treatment Centre	Treasury	5.000			1.000	2.000	2.000		10.000	In Progress

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
South Australia	Primary Health Care (PHC) delivery through community paramedicine/nurse practitioner models	Program 2.4	0.080	0.938	0.961	0.984				2.963	Executed
	Headspace Flying headspace	Program 2.1	0.066	0.198	0.198	0.198				0.660	Executed
	Drug and alcohol rehabilitation services throughout the Limestone Coast	Program 2.4		0.174	0.172	0.172				0.518	In Progress
	Drug and alcohol rehabilitation services throughout the Mt Gambier region	Program 2.4		0.824	0.822	0.822				2.468	Executed
	Construction of a new Brain and Spinal Injury facility at the Repat to meet the treatment and rehabilitation needs of people with brain and spinal injuries, relocating from existing old facilities at the Hampstead Campus	Treasury	30.000							30.000	In Progress
	Hospital Discharge Pilot to focus on the discharge of long stay hospital patients and improve patient flow	Treasury	1.700	2.249						3.949	In Progress
	Mt Barker Accident & Emergency to increase the emergency treatment spaces to respond to projected future demand	Treasury				3.000	3.000	2.600		8.600	In Progress
	South Coast A&E/Renal Victor Harbour Constructing a new six chair renal dialysis unit at Southern Fleurieu Health Service at Victor Harbor to meet projected growth. This will also support a staged redevelopment of the ward wing, incorporating up to 8 additional beds with capacity to support varying patient age profile and clinical needs, such as infectious isolation, bariatric care and disability access	Treasury					2.400	4.700	1.300	8.400	In Progress
	Whyalla Emergency Department upgrade to increase emergency treatment spaces in response to projected growth in the region	Treasury					5.700	5.660		11.360	In Progress
Northern Territory	Red Dust - Suicide Prevention for Aboriginal & Torres Strait Islander Children	Program 2.1		0.400	0.400	0.400				1.200	Executed
	Staff Accommodation Block at Tennant Creek Hospital - design and construction 12 single person accommodation units.	Treasury	0.100	0.719	2.456					3.275	In Progress
	Remote Point of Care Pathology Testing - provide the Hemocue White Blood Count and Differentials Analyser point of care machines in twenty sites across remote NT communities in Aboriginal community controlled health services and NT Health services.	Treasury	0.055	0.226	0.228	0.237				0.746	In Progress
	Ambulatory Care Centre at Alice Springs Hospital - new purpose built facility that will enhance and expand the provision of ambulatory care services at the Alice Springs Hospital	Treasury					20.700	5.000		25.700	In Progress

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
Queensland	Mater Hospital - New Maternity Block	Program 1.3	9.000							9.000	Executed
	OzCare Residential Alcohol and Drug Rehabilitation Centres - Mackay	Program 2.4	1.500	0.400	0.800	0.800	0.400			3.900	Executed
	Community residential withdrawal management service	Program 2.4		0.238	0.238	0.238				0.714	In Progress
	Bundaberg Community Diabetes Service	Program 2.4		0.238	0.238	0.238				0.714	In Progress
	Funding for PTSD at Thompson Institute	Program 2.1		2.500						2.500	In Progress
	Way Back Support Services	Program 2.1		0.400	0.400	0.400				1.200	In Progress
	Safe Spaces – alternatives to emergency departments for people in mental distress	Program 1.3				0.700	3.000	3.346	3.430	10.476	In Progress
	Mission Australia Cairns	Program 2.4		1.500	4.000	3.500				9.000	In Progress
	Pharmaceutical Rehabilitation Service	Program 2.4		0.200	0.200	0.200				0.600	In Progress
	James Cook University - Cairns Tropical Enterprise Centre	Program 1.3			8.000	16.000	18.000	18.000		60.000	In Progress
	Eating Disorders - service delivery Butterfly EndED House	Program 2.1				2.500	2.000			4.500	In Progress
	Redcliffe Hospital Paediatric ED redesign to allow for the separation of paediatric patients from adult patients	Treasury		0.500	3.300	6.200				10.000	In Progress
	Townsville Hospital to provide an additional 33 beds at the Townsville Hospital through a fit out of existing facilities	Treasury					6.000	6.980		12.980	In Progress
	Redland Hospital Redevelopment for planning and early works for redevelopment. Aim is to connect the existing renal dialysis buildings and the main hospital acute inpatient building.	Treasury					14.700	15.300		30.000	In Progress
Logan Urgent and Specialist Care Centre will operate specialist outpatient services seven days per week to relieve pressure on Logan Hospital's emergency department and specialist outpatient services.	Treasury					18.400	15.000		33.400	In Progress	
Caboolture Hospital to establish an 8 chair chemotherapy unit	Treasury						5.000	5.000	10.000	In Progress	
Improving Health Services for People with Brain and Spinal Cord Injuries and innovate new inpatient and community health services state-wide	Treasury						12.000	12.000	24.000	In Progress	

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
New South Wales	Taking an alternative road to recovery: Two mobile alcohol and other drugs (AOD) day rehabilitation programs on the NSW South Coast	Program 2.4	0.400	1.600	1.500	1.500				5.000	Executed
	Community Driven Cancer Care: Boosting Primary Care	Program 2.4	0.100	2.280	2.280	2.280				6.940	Executed
	Roses in the Ocean - Suicide Prevention & Recovery Centre St Vincent's Hospital	Program 2.1	1.250							1.250	Executed
	Comprehensive Community Based Addictions Services	Program 2.4					2.000	2.000	1.500	5.500	In Progress
	'Health on the Streets' - Homelessness Outreach - Central Coast Primary Care	Program 2.1		0.355	0.316	0.316				0.987	In Progress
	Suicide Prevention Collaborative	Program 2.1		0.500	0.500	0.500				1.500	In Progress
	Dubbo Residential Drug and Alcohol Rehabilitation Facility	Program 2.4		1.500	1.500					3.000	In Progress
	The Glen Centre - Women's Indigenous Facility	Program 2.2		4.500	1.500	1.500	1.500			9.000	In Progress
	Triple Care Farm - Batemans Bay	Program 2.4		5.000	2.000	2.000				9.000	In Progress
	Establishment of an Eating Disorders Treatment Centre	Treasury	6.500			0.500	3.500	2.500		13.000	Executed
	Concord Hospital - new maternity services	Treasury	2.200							2.200	Executed
	Shellharbour Hospital Redevelopment will deliver the remaining expansion needs and finalise the full transition to the planned hub-and-spoke model of service delivery in the Illawarra	Treasury						48.000	80.000	128.000	Executed
	Construction of a Cystic Fibrosis Specialist Service unit at Westmead Hospital. will be the anchor facility of the Westmead Health and Education Precinct which will include a 16 bed inpatient unit providing specialised treatment with state of the art equipment and modalities	Treasury				1.000	28.300	35.700		65.000	Executed
	Improving stroke care in regional NSW via telehealth will be set up for regional hospitals across NSW to access the expertise neurologists/stroke physicians	Treasury	3.800	2.800	2.800					9.400	Executed
Central Coast Linear Accelerator - the purchase of a third LINAC machine to meet expected demand	Treasury	3.853							3.853	Executed	
Comprehensive Children's Cancer Centre - to combine the scientific excellence of the 300-staff Children's Cancer Institute at UNSW Sydney with clinical leadership of the 150-staff Kids Cancer Centre at Sydney Children's Hospital, Randwick	Treasury					20.000	30.000	50.000	100.000	Executed	

Community Health and Hospitals Program

Project		Program	2018-19 (\$m)	2019-20 (\$m)	2020-21 (\$m)	2021-22 (\$m)	2022-23 (\$m)	2023-24 (\$m)	2024-25 (\$m)	Total 7-Year (\$m)	Status
Australian Capital Territory	Integration of pharmacists into aged care facilities to optimise resident safety and reduce medication-related adverse effects and hospitalisation	Program 2.5	0.816	1.835	1.083					3.734	Executed
	Community Withdrawal Support Service	Program 2.4				0.862	0.886	0.911	0.936	3.595	In Progress
	Youth Mental Health and Suicide Prevention by providing information and support to young people of the ACT when they need it most	Treasury	0.784	2.250	1.460	1.480				5.974	In Progress
	Alcohol and Other Residential Rehab Expansion and Modernisation with the aim of increasing access to community-based AOD residential rehabilitation beds to better meet current demand	Treasury					2.300	2.000		4.300	In Progress
	Establishment of an Eating Disorders Treatment Centre	Treasury				5.000	6.500	2.000		13.500	In Progress
	Expansion of the Intensive Care Unit at the Canberra Hospital	Treasury					6.700	6.800		13.500	In Progress
National	Adapting Compassion Focused Therapy for Indigenous Community Wellbeing	Program 2.2	0.400	0.400						0.800	Executed
	The Mindgardens Alliance - Black Dog Institute	Program 2.5	7.000							7.000	Executed
	Sideeffect Australia - School Drug/Alcohol Education	Program 2.4		1.000	1.000	1.000				3.000	Executed
	SANDS - Hospital to Home - Support following stillbirth	Program 2.5		0.850	0.425					1.275	In Progress
	Mates in Construction	Program 2.1		0.450	0.395	0.395				1.240	In Progress
Total										1250	

PATIENTS - Funding Agreements executed as at 30 September 2019

MRFF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	International Clinical Trials and Registries Capacity (18.1)	Murdoch Children's Research Institute	A randomised control trial of positive end-expiratory pressure levels during resuscitation of preterm infants at birth (The POLAR Trial)	Awarded - Executed	\$1,387,653.75	\$0.00	\$0.00	\$1,387,653.75	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	International Clinical Trials and Registries Capacity (18.1)	The George Institute for Global Health	The SAHaRA Trial: Understanding the best red cell transfusion practice in patients with intracranial bleeding from a ruptured aneurysm	Awarded - Executed	\$902,752.20	\$0.00	\$0.00	\$902,752.20	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	International Clinical Trials and Registries Capacity (18.1)	University of Western Australia	The Early valve replacement in severe ASymptomatic aortic stenosis (EASY AS) trial	Awarded - Executed	\$1,827,443.20	\$0.00	\$0.00	\$1,827,443.20	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	International Clinical Trials and Registries Capacity (19.1)	Macquarie University	The Australian-multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention (AU-ARROW) study	Awarded - Executed	\$3,115,063.00	\$0.00	\$0.00	\$0.00	\$3,115,063.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	International Clinical Trials and Registries Capacity (19.1)	The University of Newcastle	Sunrise Australia - A randomised clinical trial of single use negative pressure dressing for reduction in surgical site infection following emergency laparotomy.	Awarded - Executed	\$782,256.00	\$0.00	\$0.00	\$0.00	\$782,256.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	La Trobe University	Prospective, multicentre trial evaluating FET-PET in high grade glioma	Awarded - Executed	\$1,564,187.71	\$0.00	\$120,000.00	\$342,225.00	\$578,360.25	\$398,790.96	\$81,931.99	\$42,879.51	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Monash University	A collaborative study of the Interfant network (Australian sites): the feasibility, safety and efficacy of the addition of Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged Acute Lymphoblastic Leukaemia (The Blin-fant Study)	Awarded - Executed	\$314,771.57	\$0.00	\$76,544.41	\$134,960.62	\$72,596.49	\$22,605.04	\$8,065.02	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Monash University	A registry-linked national platform trial to improve precision-based outcomes using novel therapies in acute myeloid leukaemia (AML)	Awarded - Executed	\$1,507,785.35	\$0.00	\$100,593.00	\$259,488.18	\$352,799.75	\$493,275.75	\$301,628.67	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Monash University	CAST – A Randomised Phase 3 Trial of Cyclophosphamide after Sibling Allogeneic Haematopoietic Stem Cell Transplant	Awarded - Executed	\$1,570,198.12	\$0.00	\$188,462.80	\$332,044.85	\$286,917.58	\$414,769.71	\$309,996.94	\$38,006.25	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Monash University	The BLENDER Trial – Blend to Limit Oxygen in ECMO: A randomised Controlled Registry Trial	Awarded - Executed	\$753,355.46	\$0.00	\$77,021.90	\$136,697.34	\$126,262.37	\$133,242.99	\$172,511.88	\$107,618.98	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Monash University	The DIAAMOND study: Diagnosis of aplastic anaemia, management, and outcomes utilising a national dataset	Awarded - Executed	\$1,750,726.49	\$0.00	\$176,287.55	\$408,211.15	\$465,877.92	\$363,477.79	\$232,103.24	\$104,768.84	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Murdoch Children's Research Institute	The efficacy of rehabilitation for hereditary ataxias- a randomised controlled trial	Awarded - Executed	\$1,227,417.91	\$0.00	\$163,983.35	\$423,659.90	\$425,202.52	\$214,572.14	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	The University of Adelaide	Treatment of Severe Early Onset Intrahepatic Cholestasis of Pregnancy	Awarded - Executed	\$1,191,768.95	\$0.00	\$109,496.45	\$239,803.80	\$274,006.93	\$288,268.94	\$280,192.83	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	The University of Queensland	A platform clinical trial approach to the management of Mycobacterium abscessus complex (MABSC)	Awarded - Executed	\$2,091,178.43	\$0.00	\$79,867.88	\$296,401.88	\$468,850.28	\$502,317.20	\$496,096.13	\$247,645.06	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	The University of Queensland	An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies	Awarded - Executed	\$1,642,389.26	\$0.00	\$67,500.00	\$262,559.58	\$393,664.37	\$399,175.68	\$359,833.69	\$159,655.94	\$0.00

Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	The University of Queensland	Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer	Awarded - Executed	\$1,363,040.02	\$0.00	\$203,556.25	\$407,742.08	\$400,598.01	\$274,640.45	\$76,503.23	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	The University of Western Australia	BEAT-CF: Bayesian Evidence-Adaptive Trial to optimise management of Cystic Fibrosis	Awarded - Executed	\$3,545,904.97	\$0.00	\$321,912.85	\$724,389.53	\$782,825.58	\$748,814.84	\$666,560.32	\$301,401.84	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of Melbourne	SpeechAtax: A rater-blinded randomised controlled trial of intensive home-based speech treatment for ataxia	Awarded - Executed	\$498,627.29	\$0.00	\$108,061.95	\$202,634.72	\$140,821.47	\$47,109.15	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of Melbourne	STOP-MSU: Stopping haemorrhage with Tranexamic acid commenced Prehospital in a Mobile Stroke Unit	Awarded - Executed	\$1,285,820.00	\$0.00	\$139,414.78	\$263,533.58	\$247,754.67	\$251,223.25	\$254,740.36	\$129,153.36	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of New South Wales	CRISTAL: Cluster Randomised Trial of Apsirin versus Low molecular weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study	Awarded - Executed	\$934,847.73	\$0.00	\$137,229.10	\$250,602.39	\$226,024.83	\$217,075.64	\$103,915.77	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of New South Wales	Immunotherapy Targeting of Cytomegalovirus antigens in Glioblastoma: INTERROGATE-GBM	Awarded - Executed	\$1,446,001.78	\$0.00	\$306,803.50	\$596,847.50	\$362,102.36	\$126,435.76	\$53,812.66	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of Sydney	A randomised controlled trial, of N-Acetyl Cysteine, for premanifest Huntingtin gene expansion carriers (NAC-preHD)	Awarded - Executed	\$1,905,226.52	\$0.00	\$540,442.80	\$741,118.00	\$250,248.10	\$115,608.30	\$158,849.70	\$98,959.63	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	University of Sydney	The BEST-Fluids study: Better Evidence for Selecting Transplant Fluids	Awarded - Executed	\$1,117,150.38	\$0.00	\$186,435.15	\$283,375.43	\$204,154.07	\$177,241.78	\$166,364.82	\$99,579.13	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd1 Lifting Clinical Trials and Registries Capacity	Murdoch Childrens Research Institute (Australian National University)	A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics.	Awarded - Executed	\$887,071.88	\$0.00	\$192,541.50	\$395,544.16	\$250,715.57	\$48,270.65	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Deakin University	The Candesartan Adjunctive bipolar DEpression Trial - CADET	Awarded - Executed	\$2,428,397.10	\$0.00	\$0.00	\$2,103,202.70	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	La Trobe University	Improving muscle strength in young people with Prader-Willi syndrome	Awarded - Executed	\$874,179.45	\$0.00	\$0.00	\$662,125.73	\$108,726.52	\$103,327.20	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Menzies School of Health Research	Improving outcomes of children and young adults with primary ciliary dyskinesia (PCD): a multi-centre, double-blind, double-dummy, 2x2 factorial, randomised controlled trial (RCT)	Awarded - Executed	\$2,375,118.40	\$0.00	\$0.00	\$2,049,924.00	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	COZMOS: Phase I/Ib trial of Combined 5'-azacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs	Awarded - Executed	\$125,354.50	\$0.00	\$0.00	\$125,354.50	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	ErythroPOietin alfa to prevent mortality and reduce severe disability in critically ill TRAUMA patients: a multicentre, stratified, double blind, placebo randomised controlled trial. (The EPO-TRAUMA trial)	Awarded - Executed	\$3,509,303.10	\$0.00	\$0.00	\$3,184,108.70	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	Evaluating the effectiveness and safety of sodium selenate as a disease modifying treatment for patients with behavioural variant Frontotemporal Dementia (bvFTD)	Awarded - Executed	\$1,604,184.40	\$0.00	\$0.00	\$1,278,990.00	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00

Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	FaR-RMS: Frontline And Relapse study in RhabdoMyoSarcoma	Awarded - Executed	\$1,353,514.40	\$0.00	\$0.00	\$1,028,320.00	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	Novel Veneticlix Combinations to Improve Outcomes in Unfit Older Patients with Acute Myeloid Leukaemia	Awarded - Executed	\$1,380,297.60	\$0.00	\$0.00	\$1,055,103.20	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	Monash University	SJ-ELIOT: St Jude - Phase 1 Evaluation of LY2606368, Molecularly-Targeted CHK1/2i Therapy, in Combination with Cyclophosphamide or Gemcitabine for Children and Adolescents with Refractory or Recurrent Medulloblastoma Brain Tumours	Awarded - Executed	\$226,283.60	\$0.00	\$0.00	\$226,283.60	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	The University of Queensland	A Randomised Phase II Trial of Adjuvant Avelumab in Patients with Early Stage Merkel Cell Carcinoma	Awarded - Executed	\$1,632,095.75	\$0.00	\$0.00	\$1,306,901.35	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	The University of Queensland	An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma	Awarded - Executed	\$3,596,966.90	\$0.00	\$0.00	\$3,271,772.50	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	The University of Queensland	The TEACH-PD study: a Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes	Awarded - Executed	\$2,383,206.90	\$0.00	\$0.00	\$2,058,012.50	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Canberra	Evaluation of a bush medicine-based treatment for scabies in Australian Aboriginal children	Awarded - Executed	\$1,294,542.05	\$0.00	\$0.00	\$1,074,374.85	\$116,840.00	\$103,327.20	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Melbourne	The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma	Awarded - Executed	\$2,005,391.40	\$0.00	\$0.00	\$1,680,197.00	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of New South Wales	Aldosterone bloCkade for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) study	Awarded - Executed	\$2,850,898.40	\$0.00	\$0.00	\$2,525,704.00	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of New South Wales	BEAT-Calci (Better Evidence And Translation in Calciphylaxis)	Awarded - Executed	\$2,201,943.70	\$0.00	\$0.00	\$1,876,749.30	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of New South Wales	Does WithHolding Enteral feeds Around blood Transfusion reduce the incidence of necrotising enterocolitis (NEC) in very preterm infants? The international WHEAT Study	Awarded - Executed	\$1,606,825.80	\$0.00	\$0.00	\$1,281,631.40	\$116,840.00	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of New South Wales	MEMOIR: A multi-site placebo-controlled trial of memantine and graded motor imagery for complex regional pain syndrome	Awarded - Executed	\$922,314.05	\$0.00	\$0.00	\$605,233.12	\$108,726.53	\$103,327.20	\$105,027.20	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Sydney	ALS Trials Australia (ALSTA) - to develop precision medicine	Awarded - Executed	\$1,704,432.20	\$0.00	\$0.00	\$1,484,265.00	\$116,840.00	\$103,327.20	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Sydney	MAGMA: Multi-Arm GlioblastoMa Australasia Trial	Awarded - Executed	\$1,273,632.05	\$0.00	\$0.00	\$1,273,632.05	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Sydney	NAVMAN TRIAL: A multi-centre, dynamic, waitlist randomised controlled trial of patient navigators in children with chronic kidney disease	Awarded - Executed	\$1,093,680.90	\$0.00	\$0.00	\$881,627.17	\$108,726.53	\$103,327.20	\$0.00	\$0.00	\$0.00

Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Sydney	PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma.	Awarded - Executed	\$787,068.85	\$0.00	\$0.00	\$575,015.13	\$108,726.52	\$103,327.20	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd3 Rare Cancers Rare Diseases and Unmet Need Clinical Trials Program	University of Sydney	PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma	Awarded - Executed	\$1,391,472.20	\$0.00	\$0.00	\$1,391,472.20	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	La Trobe University / Olivia Newton-John Cancer Research	A Basket Study of Low Survival Cancers Treated with EGFR-ADCs	Awarded - Executed	\$1,658,626.31	\$0.00	\$0.00	\$130,000.00	\$391,119.27	\$591,952.18	\$407,360.22	\$138,194.64	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	Monash University	Brain Oxygen Neuromonitoring In Australia And New Zealand Assessment (BONANZA) Trial	Awarded - Executed	\$1,084,852.43	\$0.00	\$0.00	\$240,569.50	\$198,078.61	\$225,956.15	\$203,663.64	\$216,584.53	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	Monash University	Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study	Awarded - Executed	\$1,682,835.68	\$0.00	\$0.00	\$380,659.00	\$380,553.59	\$365,317.42	\$385,102.06	\$171,203.61	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	Monash University	Improving survival in myelofibrosis	Awarded - Executed	\$1,733,327.17	\$0.00	\$0.00	\$343,068.20	\$317,086.52	\$331,807.69	\$368,105.64	\$373,259.12	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	University of Melbourne	Combination of Avelumab with Peptide Receptor Radionuclide Therapy (PRRT) or Conventional Fractionated Radiotherapy (RT) in Metastatic Merkel Cell Carcinoma (MCC)	Awarded - Executed	\$1,812,005.42	\$0.00	\$0.00	\$651,425.50	\$640,265.46	\$305,258.54	\$215,055.92	\$0.00	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN Rd2 Low Survival Cancers and Diseases	University of Sydney	mFOLFIRINOX and STereotactic body radiotherapy (SBRT) for pancreatic cancer with high-risk and Locally AdvaNced disease (MASTERPLAN): a multicentre, randomised phase II study of the Australian Gastrointestinal Trials Group (AGITG)	Awarded - Executed	\$1,512,807.76	\$0.00	\$0.00	\$295,762.94	\$278,564.05	\$306,498.39	\$289,321.80	\$342,660.58	\$0.00
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs	RCRDUN - Building Clinical Trial Capacity	Australian Clinical Trial Alliance	Strengthening the capacity, efficiency and effectiveness of Clinical trials networks throught the Australian Clinical trial Alliance	Awarded - Executed	\$5,000,000.00	\$1,000,000.00	\$1,500,000.00	\$1,500,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Program - Brain Cancer Mission	Monash University	The PARC study: A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) Relapsed/refractory Cancers of Children and Young Adults	Awarded - Executed	\$480,015.40	\$0.00	\$0.00	\$0.00	\$240,007.70	\$240,007.70	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Program - Brain Cancer Mission	University of Melbourne	Role of the NKp44-PDGF-DD axis in Glioblastoma	Awarded - Executed	\$573,689.20	\$0.00	\$0.00	\$0.00	\$286,844.60	\$286,844.60	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Program - Brain Cancer Mission	University of Melbourne	Targeting invadopodia to treat glioblastoma	Awarded - Executed	\$384,526.00	\$0.00	\$0.00	\$0.00	\$192,263.00	\$192,263.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Beat Cancer	Cancer Council SA (SA)	Support research into the cause and potential therapies for people with cancer	Awarded - Executed	\$3,000,000.00	\$0.00	\$0.00	\$0.00	\$1,000,000.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Cardiovascular Genetic Disorders	Murdoch Children's Research Institute (Australian Genomics Health Alliance)	A project to enable the Australian Genomics Health Alliance to carry out a congenital heart disease project. The project will extend the congenital heart disease flagship study	Awarded - Executed	\$6,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$2,000,000.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00

Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Endometriosis	Jean Hailes Foundation	Investment to support research priorities identified under a National Endometriosis Action Plan. Research is likely to focus on the prevention and treatment of the condition. Awaiting outcome of a 19 February 2018 Endometriosis Roundtable to better understand priorities for investment.	Awarded - Executed	\$2,500,000.00	\$0.00	\$0.00	\$1,000,000.00	\$500,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Juvenile Diabetes	Juvenile Diabetes Research Foundation	positive impacts fo people with type 1 diabetes in Australia through support and translation of research	Awarded - Executed	\$25,000,000.00	\$0.00	\$0.00	\$0.00	\$5,000,000.00	\$5,000,000.00	\$5,000,000.00	\$5,000,000.00	\$5,000,000.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Sanfilippo Syndrome	Sanfilippo Children's Foundation (NSW)	personalised medicine approach for Australian children with Sanfilippo Syndrome (MPS III)	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$1,000,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Stem Cells	University of Melbourne Stem Cells Australia	Investment in important research projects in the stem cell / generative medicine space where Stem Cells Australia is providing a filter in terms of evaluation of scientific merit and ensuring the appropriate use of the funds.	Awarded - Executed	\$3,000,000.00	\$0.00	\$0.00	\$2,250,000.00	\$750,000.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Epilepsy	Epilepsy Foundation (Vic)	Funding for the Epilepsy Foundation to advance research into treatments including a proof-of-concept study to demonstrate how gene therapy can correct SYNGAP mutations to be conducted by the Florey Institute.	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Cerebral Palsy	Cerebral Palsy Alliance (NSW)	Funding to drive research to support the treatment of Cerebral Palsy sponsored by the Cerebral Palsy Alliance. Includes a clinical trial to test the validity of the TheraSuit conducted by the Hudson Medical Research Institute.	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Leukodystrophy (formerly Massimo's Mission)	Murdoch Children's Research Institute (The Royal Children's Hospital Melbourne)	Leukodystrophy	Awarded - Executed	\$3,000,000.00	\$0.00	\$0.00	\$1,000,000.00	\$1,000,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Adults with Motor Neuron Disease (MND)	Cure for MND Foundation	Extended investment via Cure4MND Foundation who previously received \$2m under the MRFF Accelerated Research program in 2016-17, and prior to that \$2.8m as part of a 2016 Coalition Election Commitment. Investment will support clinical trials and related research activities and project continuity.	Awarded - Executed	\$1,960,000.00	\$1,960,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Adults with Motor Neuron Disease (MND)	Cure for MND Foundation		Awarded - Executed	\$6,000,000.00	\$0.00	\$2,000,000.00	\$2,000,000.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Microbiome	St George and Sutherland Medical Research Foundation	studies on the role of the gut microbiome in health and disease	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$1,000,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Australian National Phenome Centre	Murdoch University	To establish the Australian National Phenome Centre	Awarded - Executed	\$10,000,000.00	\$0.00	\$0.00	\$10,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Olivia Newton-John Cancer Research Institute	Olivia Newton-John Cancer Research Institute (Vic)	Rare Cancer trial - combination treatment with Ipilimumab and Nivolumab at rural sites	Awarded - Executed	\$1,000,000.00	\$0.00	\$0.00	\$500,000.00	\$500,000.00	\$0.00	\$0.00	\$0.00	\$0.00

Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Bone Marrow Failure Syndromes	Maddie Riewoldt's Vision (Vic)	Maddie Riewoldt's Vision will be funded to run Clinical Fellowships to build capacity with research nurses, key clinical trial infrastructure, statistical support and/or add value to existing clinical trials through the collection and analysis of correlative samples.	Awarded - Executed	\$1,000,000.00	\$0.00	\$0.00	\$350,000.00	\$350,000.00	\$300,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Drug discovery	Walter and Eliza Hall Institute of Medical Research	National Drug Discovery Centre	Awarded - Executed	\$25,000,000.00	\$0.00	\$0.00	\$15,000,000.00	\$0.00	\$5,000,000.00	\$5,000,000.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Teencancer - Canteen (NSW)	Canteen (NSW)	Supporting new clinical trials for adolescents and young adults with cancer	Awarded - Executed	\$5,000,000.00	\$5,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Stillbirth	The University of Queensland	Stillbirth	Awarded - Executed	\$3,000,000.00	\$0.00	\$0.00	\$1,000,000.00	\$1,000,000.00	\$1,000,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Stroke	Stroke Foundation (Vic)	Funding is being utilised to develop the Australia Living Guidelines for Stroke Management and a targeted clinical research investment in stroke recovery for young survivors titled "return to life, return to work".	Awarded - Executed	\$2,500,000.00	\$0.00	\$0.00	\$2,000,000.00	\$250,000.00	\$250,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Parkinson's Disease	Garvan Institute of Medical Research	Parkinson's disease Shake it Up	Awarded - Executed	\$30,000,000.00	\$0.00	\$0.00	\$6,000,000.00	\$6,000,000.00	\$6,000,000.00	\$6,000,000.00	\$6,000,000.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Phenomics Capability	Australian National University	Phenomics capability	Awarded - Executed	\$10,000,000.00	\$0.00	\$0.00	\$10,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Prostate Cancer	Movember Foundation	The Australian Prostate Cancer Research Centres will be funded to build prostate cancer research capacity in Australia.	Awarded - Executed	\$6,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$2,000,000.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00
Emerging Priorities and Consumer Driven Research (EPCDR)	Accelerated Research Malaria Vaccine	Griffith University	A Vaccine for Malaria	Awarded - Executed	\$500,000.00	\$0.00	\$0.00	\$500,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	Tackling Antimicrobial Resistance Program	Monash University	Stepped-wedge Trial to increase antibiotic Appropriateness in Residential aged care facilities and model Transmission of antimicrobial resistance (The START Research Program)	Awarded - Executed	\$1,826,398.82	\$0.00	\$123,310.25	\$464,091.73	\$641,835.93	\$448,658.54	\$148,502.37	\$0.00	\$0.00
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	Tackling Antimicrobial Resistance Program	South Australian Health and Medical Research Institute	Using metagenomics and the Registry of Ageing South Australians to understand carriage and transmission of antimicrobial resistance in the elderly	Awarded - Executed	\$1,731,373.66	\$0.00	\$194,964.60	\$710,955.25	\$671,890.20	\$153,563.61	\$0.00	\$0.00	\$0.00
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	Tackling Antimicrobial Resistance Program	The University of Queensland	Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities	Awarded - Executed	\$1,199,975.86	\$0.00	\$60,258.30	\$312,091.40	\$543,274.35	\$284,351.81	\$0.00	\$0.00	\$0.00
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	Tackling Antimicrobial Resistance Program	University of South Australia	Turning antimicrobial resistance in residential aged care inside-out from the patient to facility level	Awarded - Executed	\$1,142,251.65	\$0.00	\$108,203.88	\$293,332.18	\$340,199.00	\$277,494.62	\$123,021.97	\$0.00	\$0.00
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	National Security Against Pandemic Risk	Coalition for Epidemic Preparedness Innovations	Pandemic vaccine development	Awarded - Executed	\$2,000,000.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
TOTALS					\$249,516,427.03	\$7,960,000.00	\$9,282,892.25	\$110,741,644.53	\$42,866,590.51	\$36,760,107.06	\$23,333,621.67	\$13,571,571.01	\$5,000,000.00

MRFF 10 Year investment plan - Budget, committed and not yet committed funding

MRFF Stream	MRFF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Translation	Medical Research Commercialisation	Biomedical Translation Bridge Program (MTPConnect)	MTP Connect	Biomedical Translation Bridge	Awarded - Executed	\$22,300,000.00	\$0.00	\$0.00	\$10,400,000.00	\$5,300,000.00	\$5,300,000.00	\$1,300,000.00	\$0.00	\$0.00
Translation	Medical Research Commercialisation	BioMedTech Horizons Program 1 - Via MTPConnect	MTPConnect	BioMedTech Horizons Program (Rd 1)	Awarded - Executed	\$10,000,000.00	\$0.00	\$10,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Medical Research Commercialisation	BioMedTech Horizons Program 2 & 3 - Via MTPConnect	MTPConnect	BioMedTech Horizons Program (Rd 2 & 3)	Awarded - Executed	\$35,000,000.00	\$0.00	\$0.00	\$5,000,000.00	\$10,000,000.00	\$20,000,000.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - targeted grant opportunity	University of Canberra	Environmental and social determinants of health in the Australian Capital Territory: program interventions aimed at reducing the burden of disease and avoidable hospital admissions.	Awarded - Executed	\$4,000,000.00	\$0.00	\$0.00	\$4,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - targeted grant opportunity	University of Tasmania	Risk Reduction for Dementia Intervention- North West (RREDI-NOW) - an initiative of the Wicking Centre 'Island Study Linking Ageing and Neurodegenerative Disease (ISLAND)' & CAPITOL project	Awarded - Executed	\$2,400,000.00	\$0.00	\$0.00	\$800,000.00	\$800,000.00	\$800,000.00	\$0.00	\$0.00	\$0.00

Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Baker Heart and Diabetes Institute	Reduction of Heart Failure Readmission in Resource-Constrained Environments: Supporting Nurse-led Disease Management by Risk-Guidance and eHealth	Awarded - Executed	\$287,662.90	\$0.00	\$0.00	\$287,662.90	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	La Trobe University	Reducing inappropriate knee joint replacement surgery and hospital burden	Awarded - Executed	\$1,337,750.00	\$0.00	\$0.00	\$447,090.00	\$499,150.00	\$391,510.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	La Trobe University	Transforming pulmonary rehabilitation to reduce hospital admissions in COPD	Awarded - Executed	\$1,220,668.40	\$0.00	\$0.00	\$460,930.30	\$443,918.00	\$315,820.10	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Macquarie University	Harnessing implementation science, complexity science and evidence-based care to Keep Australians Out of Hospital: leveraging seven natural experiments in New South Wales	Awarded - Executed	\$1,505,612.00	\$0.00	\$0.00	\$490,204.00	\$505,204.00	\$510,204.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Queensland University of Technology	An early detection program to prevent unnecessary hospital admissions of aged care residents	Awarded - Executed	\$1,898,519.30	\$0.00	\$0.00	\$506,150.60	\$899,138.60	\$493,230.10	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Queensland University of Technology	Local Assessment and Triage Evaluation of NAFLD (LOCATE-NAFLD)	Awarded - Executed	\$969,193.00	\$0.00	\$0.00	\$235,206.00	\$381,481.00	\$352,506.00	\$0.00	\$0.00	\$0.00

Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	The Enhance care study: multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer	Awarded - Executed	\$1,061,521.50	\$0.00	\$0.00	\$270,716.50	\$344,005.00	\$446,800.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	The Resilience to Seasonal Illness and Increased Emergency admissions Care (RESILIENCE) Study	Awarded - Executed	\$1,284,327.00	\$0.00	\$0.00	\$462,950.90	\$451,751.70	\$369,624.40	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	There's no place like home: national scale up of the paediatric low risk febrile neutropenia program	Awarded - Executed	\$1,237,016.00	\$0.00	\$0.00	\$486,771.50	\$388,396.00	\$361,848.50	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Technology Sydney	Translation of best practice osteoporosis refractor prevention: stopping fragility fractures to keep Australians out of hospital	Awarded - Executed	\$897,729.90	\$0.00	\$0.00	\$230,290.80	\$347,215.80	\$320,223.30	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd2	The University of Adelaide	Mobile X-ray services provided within residential aged care facilities	Awarded - Executed	\$1,970,000.00	\$0.00	\$0.00	\$630,000.00	\$610,000.00	\$730,000.00	\$0.00	\$0.00	\$0.00

Translation	Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd2	University of Tasmania	ANCHOR Project: health economics and epidemiology of magic encephalomyelitis/chronic fatigue syndrome	Awarded - Executed	\$155,000.00	\$0.00	\$0.00	\$95,000.00	\$55,000.00	\$5,000.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd1	Monash University	Assessing diagnostic accuracy for melanoma with compared to without access to Melanoma Surveillance Photography in high-risk individuals	Awarded - Executed	\$2,416,998.00	\$0.00	\$0.00	\$1,034,528.00	\$619,528.00	\$762,942.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd1	University of Western Australia	Evaluation of clinical pathways and patient outcomes for breast MRI in preoperative assessment and staging of breast cancer: Establishing when MRI improves patient outcomes and when it does not.	Awarded - Executed	\$2,072,217.00	\$0.00	\$0.00	\$1,003,805.00	\$752,420.00	\$315,992.00	\$0.00	\$0.00	\$0.00
Translation	Preventative and Public Health Research	Boosting Preventive Health Research Program Via Sax institute	Sax Institute	The Australian Prevention Partnership Centre (TAPPC)	Awarded - Executed	\$10,000,000.00	\$10,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	Monash University Monash Partners	Monash Partners Advanced Health Translation Centre – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,131,439.00	\$0.00	\$0.00	\$0.00	\$2,065,719.50	\$2,065,719.50	\$0.00	\$0.00	\$0.00

Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	The University of Queensland Brisbane Diamantina Health Partners	Brisbane Diamantina Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000.00	\$0.00	\$0.00	\$0.00	\$2,055,000.00	\$2,055,000.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Melbourne Melbourne Academic Centre for Health (MACH)	Melbourne Academic Centre for Health – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,431,900.00	\$0.00	\$0.00	\$0.00	\$2,215,950.00	\$2,215,950.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Sydney Sydney Health Partners	Sydney Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,118,000.00	\$0.00	\$0.00	\$0.00	\$2,059,000.00	\$2,059,000.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Western Australia WA Health Translation Network (WAHTN)	Western Australian Health Translation Network – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,138,000.00	\$0.00	\$0.00	\$0.00	\$2,069,000.00	\$2,069,000.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Newcastle NSW Regional Health Partners	NSW Regional Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000.00	\$0.00	\$0.00	\$0.00	\$2,055,000.00	\$2,055,000.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	South Australian Health and Medical Research Institute (SAHMRI)	Health Translation SA – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000.00	\$0.00	\$0.00	\$0.00	\$2,055,000.00	\$2,055,000.00	\$0.00	\$0.00	\$0.00

Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of NSW The Sydney Partnership for Health, Education and Research Enterprise (SPHERE)	Maridulu Budyari Gumal Sydney Partnership for Health Education Research and Enterprise (SPHERE)– MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000.00	\$0.00	\$0.00	\$0.00	\$2,055,000.00	\$2,055,000.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	Monash University	Monash Partners	Awarded - Executed	\$1,978,561.00	\$0.00	\$0.00	\$1,978,561.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	The University of Queensland	Brisbane Diamantina Health Partners	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Melbourne	Melbourne Academic Centre for Health (MACH)	Awarded - Executed	\$1,678,100.00	\$0.00	\$0.00	\$1,678,100.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Sydney	Sydney Health Partners - Transformative translational research and National system initiatives	Awarded - Executed	\$1,992,000.00	\$0.00	\$0.00	\$1,992,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Western Australia	WA Health Translation Network (WAHTN)	Awarded - Executed	\$1,972,000.00	\$0.00	\$0.00	\$1,972,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	Central Australia Academic Health Science Centre	Central Australian Aboriginal Congress	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Newcastle NSW Regional Health Partners	NSW Regional Health Partners	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	South Australian Health and Medical Research Institute (SAHMRI)	SAHMRI Rapid Applied Research Translation Program	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of NSW	The Sydney partnership for Health, Education and Research Enterprise (SHERE)	Awarded - Executed	\$2,000,000.00	\$0.00	\$0.00	\$2,000,000.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	Monash University Monash Partners	Monash Partners Rapid Translation Projects - Component A	Awarded - Executed	\$2,222,222.00	\$0.00	\$2,222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	The University of Queensland	Brisbane Diamantina Health Partners	Awarded - Executed	\$222,222.00	\$0.00	\$222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Melbourne	Melbourne Academic Centre for Health (MACH)	Awarded - Executed	\$2,222,222.00	\$0.00	\$2,222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Sydney Sydney Health Partners	Transformative translational research and National system initiatives	Awarded - Executed	\$2,222,222.00	\$0.00	\$2,222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Western Australia WA Health Translation Network (WAHTN)	Collaborative research into national system level initiative/s Component B	Awarded - Executed	\$222,222.00	\$0.00	\$222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	Central Australia Academic Health Science Centre	Central Australian Aboriginal Congress	Awarded - Executed	\$222,222.00	\$0.00	\$222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Newcastle	NSW Regional Health Partners	Awarded - Executed	\$222,222.00	\$0.00	\$222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	South Australian Health and Medical Research Institute	SAHMRI Rapid Applied Research Translation Program	Awarded - Executed	\$2,222,222.00	\$0.00	\$2,222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of NSW	Sydney Partnership for Health Education Research and Enterprise (SPHERE)	Awarded - Executed	\$222,222.00	\$0.00	\$222,222.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

Totals					\$ 574,475,969.73	\$ 17,960,000.00	\$ 32,097,470.47	\$ 189,931,633.53	\$ 133,331,335.51	\$ 122,706,039.46	\$ 51,007,449.17	\$ 20,067,144.94	\$ 5,439,734.65
Notes:													
<i>Clinical Researchers funding agreements include indexation and a stipend which is calculated separately by NHMRC and is additional to the above funding amounts.</i>													
<i>A total of 72 Clinical Researchers funding agreements are executed as at 30 September 2019, out of a total of 74 Clinical Researcher grants awarded (i.e. 2 did not progress to execution of a funding agreement).</i>													

Medical Research Future Fund 10 Year Plan - including a breakdown of committed, allocated and not yet allocated funding as at 30 September 2019

	2016-17 Actual \$m	2017-18 Actual \$m	2018-19 Budget \$m	2018-19 Actual \$m	2019-20 Budget \$m	2019-20 Committed \$m	2019-20 Grant Rounds in progress \$m	2019-20 Not yet allocated \$m	2020-21 Budget \$m	2020-21 Committed \$m	2020-21 Grant Rounds in progress \$m	2020-21 Not yet allocated	2021-22 Budget \$m	2021-22 Committed \$m	2021-22 Grant Rounds in progress \$m	2021-22 Not yet allocated \$m	2022-23 Budget \$m	2022-23 Committed \$m	2022-23 Grant Rounds in progress \$m	2022-23 Not yet allocated \$m	2023-24 Budget \$m	2023-24 Committed \$m	2023-24 Grant Rounds in progress \$m	2023-24 Not yet allocated \$m	2024-25 Budget \$m	2025-26 Budget \$m	2026-27 Budget \$m	2027-28 Budget \$m	TOTAL BUDGET \$m	TOTAL COMMITTED \$m	
Patients totals	8.0	7.3	97.8	112.5	124.4	43.1	18.5	62.8	140.3	36.8	20.5	83.1	146.5	23.5	17.6	105.4	135.1	13.4	15.7	106.0	129.1	5.0	9.5	114.6	125.6	125.6	125.6	125.6	1,275.6	249.5	
Emerging Priorities and Consumer Driven Research (EPCD)	7.0	-	53.7	63.4	54.3	25.3	10.1	18.9	71.2	26.3	20.5	24.4	80.9	16.0	17.6	47.3	69.5	11.0	15.7	42.8	63.5	5.0	9.5	49.0	60.0	60.0	60.0	60.0	633.1	153.9	
Clinical Trials for Rare Cancers, Rare Diseases and Unmet Needs (RCRDUN)	1.0	4.8	42.3	47.4	67.1	15.6	8.4	43.1	66.5	9.3		57.2	62.6	7.2	-	55.4	62.6	2.4	-	60.2	62.6	-	-	62.6	62.6	62.6	62.6	62.6	614.1	87.7	
Global Health - Tackling Antimicrobial Resistance and Drug Resistant Tuberculosis	-	2.5	1.8	1.8	3.0	2.2		0.8	2.7	1.2		1.5	3.0	0.3	-	2.7	3.0	-	-	3.0	3.0	-	-	3.0	3.0	3.0	3.0	3.0	28.4	7.9	
Researchers totals	-	1.8	4.3	4.9	49.8	15.7	8.0	26.1	92.6	5.3	10.0	77.2	102.1	3.7	10.0	88.4	94.0	1.8	4.0	88.2	90.0	0.4	-	89.6	90.0	90.0	90.0	90.0	792.8	33.7	
Frontier Health and Medical Research	-	-	-	-	20.0	9.5		10.5	60.0	-	-	60.0	70.0	-	-	70.0	70.0	-	-	70.0	70.0	-	-	70.0	70.0	70.0	70.0	70.0	70.0	570.0	9.5
Industry Researcher Exchange and Training	-	-	-	-	8.0	-	8.0	-	10.0	-	10.0	-	10.0	-	10.0	-	4.0	-	4.0	-	-	-	-	-	-	-	-	-	-	32.0	-
Clinical Researchers	-	1.8	4.3	4.9	21.8	6.2		15.6	22.6	5.3		17.2	22.1	3.7		18.4	20.0	1.8		18.2	20.0	0.4	-	19.6	20.0	20.0	20.0	20.0	190.8	24.2	
Missions totals	-	1.0	47.8	44.7	140.6	31.1	19.2	90.3	175.7	33.0	19.9	122.8	166.9	13.0	18.6	135.3	161.9	4.9	8.0	148.9	148.0	0.3	-	147.7	148.0	138.0	138.0	119.2	1,384.0	128.1	
Australian Brain Cancer Mission	-	1.0	9.0	4.7	5.0	2.0	-	3.0	5.0	2.0	-	3.0	5.0	2.0	-	3.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	5.0	5.0	-	49.0	11.8	
Million Minds Mental Health Research Mission	-	-	5.0	6.2	5.0	5.0	-	-	15.0	5.9	-	9.1	15.0	5.8	-	9.2	25.0	4.6	-	20.4	15.0	-	-	15.0	20.0	10.0	10.0	5.0	125.0	27.5	
Genomics Health Futures Mission	-	-	8.8	8.8	56.6	14.1	19.2	23.3	68.7	15.2	19.9	33.6	69.9	5.2	18.6	46.1	54.9	0.3	8.0	46.5	50.0	0.3	-	49.7	50.0	50.0	50.0	41.2	500.0	43.9	
Ageing, Aged Care and Dementia Mission	-	-	10.0	10.0	17.5	-	-	17.5	17.5	-	-	17.5	17.5	-	-	17.5	17.5	-	-	17.5	17.5	-	-	17.5	17.5	17.5	17.5	17.5	17.5	167.5	10.0
Indigenous Health Futures Mission	-	-	15.0	15.0	22.5	10.0	-	12.5	22.5	10.0	-	12.5	12.5	-	-	12.5	12.5	-	-	12.5	12.5	-	-	12.5	12.5	12.5	12.5	12.5	12.5	147.5	35.0
Stem Cell Mission	-	-	-	-	6.0	-	-	6.0	18.0	-	-	18.0	18.0	-	-	18.0	18.0	-	-	18.0	18.0	-	-	18.0	18.0	18.0	18.0	18.0	18.0	150.0	-
Cardiovascular Mission	-	-	-	-	23.0	-	-	23.0	24.0	-	-	24.0	24.0	-	-	24.0	24.0	-	-	24.0	25.0	-	-	25.0	20.0	20.0	20.0	20.0	20.0	200.0	-
Traumatic Brain Injury Mission	-	-	-	-	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	5.0	5.0	5.0	5.0	45.0	-
Translation totals	10.0	20.0	54.2	44.2	77.8	39.3	2.1	36.4	171.2	48.1	2.1	121.0	212.0	1.3	-	210.7	176.5	-	-	176.5	173.5	-	-	173.5	163.5	163.5	163.8	163.8	1,519.7	162.9	
Preventative and Public Health Research	10.0	-	18.8	11.2	32.5	7.4	-	25.1	57.1	6.2	-	50.9	33.5	-	-	33.5	29.5	-	-	29.5	26.5	-	-	26.5	15.5	15.5	15.8	15.8	260.4	34.7	
Primary Health Care Research	-	-	-	-	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	-	-	5.0	5.0	5.0	5.0	5.0	5.0	45.0	-
Rapid Applied Research Translation Centres	-	10.0	20.0	17.6	20.0	16.6	2.1	1.3	20.0	16.6	2.1	1.3	22.0	-	-	22.0	22.0	-	-	22.0	22.0	-	-	22.0	23.0	23.0	23.0	23.0	218.0	60.9	
Medical Research Commercialisation	-	10.0	15.4	15.4	15.3	15.3	-	-	35.3	25.3	-	10.0	35.3	1.3	-	34.0	35.0	-	-	35.0	35.0	-	-	35.0	35.0	35.0	35.0	35.0	311.3	67.3	
National Critical Research Infrastructure	-	-	-	-	5.0	-	-	5.0	43.8	-	-	43.8	106.2	-	-	106.2	75.0	-	-	75.0	75.0	-	-	75.0	75.0	75.0	75.0	75.0	75.0	605.0	-
Data Infrastructure - Registries, biobanks, linkage platforms	-	-	-	-	-	-	-	-	10.0	-	-	10.0	10.0	-	-	10.0	10.0	-	-	10.0	10.0	-	-	10.0	10.0	10.0	10.0	10.0	80.0	-	
TOTALS	18.0	30.1	204.1	206.4	392.6	129.2	47.8	215.7	579.8	123.2	52.5	404.1	627.5	41.5	46.2	539.8	567.5	20.2	27.7	519.6	540.6	5.7	9.5	525.4	527.1	517.1	517.4	498.6	4,972.1	574.2	

Note:
 Actuals = Amount expended as published in Annual Reports.
 Commitments = Executed funding agreements between the Commonwealth and funding recipients.

Medical Research Future Fund - Funding Agreements in progress not yet executed as at 30 September 2019

MRFF Stream	MRFF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Missions	Genomics Health Futures Mission	Genomics - Investigator Grant Rd 1	The University of Queensland	The history of the human genome and the mechanisms of genomic disease	Under Offer	\$1,554,485	\$0	\$0	\$0	\$1,399,037	\$0	\$155,449	\$0	\$0
Translation	Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	Central Australia Academic Health Science Centre	Central Australian Aboriginal Congress	Under Offer	\$4,110,000	\$0	\$0	\$0	\$2,055,000	\$2,055,000	\$0	\$0	\$0
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Autism Spectrum Disorders	Monash University	Autism Spectrum Disorders	To be offered	\$2,500,000	\$0	\$0	\$0	\$500,000	\$500,000	\$500,000	\$500,000	\$500,000
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Male infertility	University of NSW	Male infertility	To be offered	\$3,800,000	\$0	\$0	\$0	\$800,000	\$1,000,000	\$1,000,000	\$1,000,000	\$0
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Children's Cancer Research	Children's Cancer Foundation	To ensure children with cancer have the best chance of survival through a range of clinical trials and research projects	To be offered	\$9,600,000	\$0	\$0	\$0	\$0	\$3,200,000	\$3,200,000	\$3,200,000	\$0
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Lung Cancer Genomics Project	Roche		To be offered	\$5,000,000	\$0	\$0	\$0	\$2,500,000	\$2,500,000	\$0	\$0	\$0
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Multiple Sclerosis.	University of Tasmania Menzies Institute	Multiple Sclerosis.	To be offered	\$10,000,000	\$0	\$0	\$0	\$1,000,000	\$2,000,000	\$2,000,000	\$2,000,000	\$3,000,000
Patients	Emerging Priorities and Consumer Driven Research (EPCDR)	Women in Sport	Victoria University	Women in Sport	To be offered	\$1,000,000	\$0	\$0	\$0	\$300,000	\$300,000	\$400,000	\$0	\$0
Totals						\$37,564,485	\$0	\$0	\$0	\$8,554,037	\$11,555,000	\$7,255,449	\$6,700,000	\$3,500,000

MISSIONS - Funding Agreements executed as at 30 September 2019

MRFF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Ageing, Aged Care and Dementia Mission	Accelerated Research (EPCDR) Dementia	The University of Queensland (Clem Jones Centre for Ageing and Dementia Research)	Breaking through dementia - the Clem Jones Centre for Ageing Dementia Research	Awarded - Executed	\$10,000,000	\$0	\$0	\$10,000,000	\$0	\$0	\$0	\$0	\$0
Australian Brain Cancer Mission	Australian and New Zealand Children's Haematology/Oncology Group	Monash University	Australian and New Zealand Children's Haematology/Oncology Group	Awarded - Executed	\$2,500,000	\$0	\$0	\$1,000,000	\$500,000	\$500,000	\$500,000	\$0	\$0
Australian Brain Cancer Mission	Cooperative Trials Group for Neuro-Oncology	University of Sydney	Cooperative Trials Group for Neuro-Oncology	Awarded - Executed	\$2,500,000	\$0	\$0	\$1,000,000	\$500,000	\$500,000	\$500,000	\$0	\$0
Australian Brain Cancer Mission	Zero Childhood Cancer	University of New South Wales	Zero Childhood Cancer - Personalised medicine program for children who have less than a 30% 5 year survival rate	Awarded - Executed	\$5,002,023	\$0	\$1,002,023	\$1,000,000	\$1,000,000	\$1,000,000	\$1,000,000	\$0	\$0
Australian Brain Cancer Mission	Innovative Clinical Trials	La Trobe University	Prospective, multicentre trial evaluating FET-PET in high grade glioma (FIG Study)	Awarded - Executed	\$1,246,612	\$0	\$0	\$1,246,612	\$0	\$0	\$0	\$0	\$0
Australian Brain Cancer Mission	Innovative Clinical Trials	University of Sydney	LUMOS (Low & Intermediate Grade Glioma Umbrella Study of Molecular Guided Therapies)	Awarded - Executed	\$502,558	\$0	\$0	\$502,558	\$0	\$0	\$0	\$0	\$0
Genomics Health Futures Mission	Mackenzie's Mission	Murdoch Children's Research Institute (leveraging Australian Genomics)	Mackenzie's Mission: The Australian Reproductive Carrier Screening Project	Awarded - Executed	\$19,982,540	\$0	\$0	\$3,087,628	\$7,055,006	\$9,839,906	\$0	\$0	\$0
Genomics Health Futures Mission	ProCan	University of Sydney (administering for the Children's Medical Research Institute)	ProCan: The human cancer proteome project	Awarded - Executed	\$20,400,000	\$0	\$0	\$5,700,000	\$5,000,000	\$5,000,000	\$4,700,000	\$0	\$0
Genomics Health Futures Mission	Genomics - Investigator Grant Rd 1	The Walter and Eliza Hall Institute of Medical Research	Statistical methods for analyzing next generation sequencing data	Awarded - Executed	\$639,750	\$0	\$0	\$0	\$575,775	\$0	\$63,975	\$0	\$0
Genomics Health Futures Mission	Genomics - Investigator Grant Rd 1	University of New South Wales	Developing synthetic DNA reference standards (sequins) to ensure accuracy in emerging genomic techniques	Awarded - Executed	\$1,443,588	\$0	\$0	\$0	\$1,299,229	\$0	\$144,359	\$0	\$0
Indigenous Health Futures Mission	Accelerated Research Rheumatic Heart Disease	Telethon Kids Institute University of Western Australia	Vaccine to combat Rheumatic Heart Disease	Awarded - Executed	\$35,000,000	\$0	\$0	\$0	\$15,000,000	\$10,000,000	\$10,000,000	\$0	\$0

Million Minds Mental Health Research Mission	Million Minds Rd 1	Curtin University	Our Journey, Our Story: Building bridges to improve Aboriginal youth mental health and wellbeing	Awarded - Executed	\$2,459,030	\$0	\$0	\$595,744	\$326,696	\$490,872	\$560,466	\$485,253	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	Deakin University	Leveraging digital technology to reduce the prevalence and severity of eating disorders in Australia	Awarded - Executed	\$1,342,548	\$0	\$0	\$499,380	\$198,040	\$327,564	\$317,564	\$0	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	Monash University	The Kids are Not Okay: Emergency Department management of acute mental health crises in children and young people	Awarded - Executed	\$4,996,127	\$0	\$0	\$932,486	\$1,062,971	\$1,132,496	\$1,133,303	\$734,871	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	University of Melbourne	Bringing family, community, culture and country to the centre of health care: culturally appropriate models for improving mental health and wellbeing in Aboriginal and Torres Strait Islander young people	Awarded - Executed	\$4,998,864	\$0	\$0	\$730,069	\$1,062,271	\$1,171,970	\$1,137,907	\$896,647	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	University of Southern Queensland	Translating evidence-based interventions into population-level digital models of care for child and adolescent mental health	Awarded - Executed	\$4,996,351	\$0	\$0	\$1,495,591	\$866,408	\$975,661	\$884,887	\$773,804	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	University of Sydney	MAINSTREAM Centre for Health System Research & Translation in Eating Disorders: detection and intervention system-focused knowledge to drive better outcomes in mainstream care for eating disorders	Awarded - Executed	\$3,670,400	\$0	\$0	\$750,271	\$641,639	\$761,163	\$756,163	\$761,163	\$0
Million Minds Mental Health Research Mission	Million Minds Rd 1	University of Western Australia	Generating Indigenous patient-centred, clinically and culturally capable models of mental health care	Awarded - Executed	\$4,991,608	\$0	\$0	\$1,191,024	\$841,975	\$1,016,500	\$961,055	\$981,055	\$0
TOTALS					\$126,671,998	\$0	\$1,002,023	\$29,731,363	\$35,930,010	\$32,716,131	\$22,659,678	\$4,632,793	\$0

The difference in total committed above and in the MRFF 10 year plan breakdown, is due to an administrative issue in grant hub reporting system.

RESEARCHERS - Funding Agreements executed as at 31 September 2019

MRRF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Clinical Researchers	Researchers	Australian National University	Implementation of a peer worker-led mental health recovery program	Awarded - Executed	\$179,118	\$0	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0
Clinical Researchers	Researchers	Burnet Institute	Advancing diagnostics and vaccines for malaria elimination	Awarded - Executed	\$437,036	\$0	\$0	\$54,630	\$109,259	\$109,259	\$109,259	\$54,630	\$0
Clinical Researchers	Researchers	University of Melbourne -	Improving patient management pathways in age-related macular degeneration	Awarded - Executed	\$179,118	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	Curtin University	Pharmacy Interventions for Naloxone Scale-Up (PINS)	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	Deakin University	Translating dignity principles into practice in aged care homes	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	Flinders University of South Australia	Enhancing the capacity of mental health services to review, personalise and intervene early through implementation of real-time outcome monitoring	Awarded - Executed	\$179,118	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	Florey Institute of Neuro-science and Mental Health	Mild traumatic brain injury and the risk of long-term neurodegenerative and neurobehavioural disease	Awarded - Executed	\$577,189	\$0	\$57,719	\$115,438	\$115,438	\$115,438	\$115,438	\$57,719	\$0
Clinical Researchers	Researchers	Garvan Institute of Medical Research	Improving outcomes in osteoporosis and bone health	Awarded - Executed	\$343,683	\$0	\$34,368	\$68,737	\$68,737	\$68,737	\$68,737	\$34,368	\$0
Clinical Researchers	Researchers	La Trobe University	Implementing appropriate exercise and education for Australians with knee osteoarthritis	Awarded - Executed	\$179,118	\$0	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0
Clinical Researchers	Researchers	La Trobe University	Translating evidence to improve access to paediatric therapy services	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	Monash University	A national cancer outcome strategy	Awarded - Executed	\$487,893	\$0	\$0	\$48,789	\$97,579	\$97,579	\$97,579	\$97,579	\$48,789

Clinical Researchers	Researchers	Monash University	Cognitive Phenotyping and Personalised Treatment for Methamphetamine Addiction	Awarded - Executed	\$476,728	\$0	\$59,591	\$119,182	\$119,182	\$119,182	\$59,591	\$0	\$0
Clinical Researchers	Researchers	Monash University	fungai: Breaking the mould of the traditional antifungal stewardship paradigm	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	Monash University	Generating and translating evidence into practice in women's health and beyond	Awarded - Executed	\$494,733	\$0	\$49,473	\$98,947	\$98,947	\$98,947	\$98,947	\$49,473	\$0
Clinical Researchers	Researchers	Monash University	Improving outcomes for critically ill patients after traumatic brain injury and blood transfusion	Awarded - Executed	\$412,278	\$0	\$41,228	\$82,456	\$82,456	\$82,456	\$82,456	\$41,228	\$0
Clinical Researchers	Researchers	Monash University	Improving outcomes in low back pain: Targeting specific therapies to patient subgroups	Awarded - Executed	\$429,055	\$0	\$53,632	\$107,264	\$107,264	\$107,264	\$53,632	\$0	\$0
Clinical Researchers	Researchers	Monash University	Next Generation Targeting of DNA-Methylation in Poor Risk Lymphoid Cancer	Awarded - Executed	\$218,518	\$0	\$0	\$27,315	\$54,630	\$54,630	\$54,630	\$27,315	\$0
Clinical Researchers	Researchers	Monash University	Novel targeted onco-theranostic nanoparticles for personalised therapy and real-time monitoring	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0
Clinical Researchers	Researchers	Monash University	Optimising Emergency and Trauma Systems through evidence based pathways	Awarded - Executed	\$412,278	\$0	\$41,228	\$82,456	\$82,456	\$82,456	\$82,456	\$41,228	\$0
Clinical Researchers	Researchers	Monash University	Precision medicine for epilepsy and beyond: from discovery to implementation and evaluation	Awarded - Executed	\$481,156	\$0	\$48,116	\$96,231	\$96,231	\$96,231	\$96,231	\$48,116	\$0
Clinical Researchers	Researchers	Monash University	Reducing Brain Injury and Improving The Care Of High-Risk Newborn Infants	Awarded - Executed	\$241,702	\$0	\$0	\$30,213	\$60,426	\$60,426	\$60,426	\$30,213	\$0

Clinical Researchers	Researchers	Monash University	Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia	Awarded - Executed	\$412,419	\$0	\$41,242	\$82,484	\$82,484	\$82,484	\$82,484	\$41,242	\$0
Clinical Researchers	Researchers	Murdoch Children's Research Institute	Implementing evidence based management for children with dystonic cerebral palsy	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	Murdoch Children's Research Institute	Improving the health and development of high risk preterm newborns	Awarded - Executed	\$333,710	\$0	\$41,714	\$83,427	\$83,427	\$83,427	\$41,714	\$0	\$0
Clinical Researchers	Researchers	Murdoch Children's Research Institute	Improving upper limb function in Hereditary Cerebellar Ataxia	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0
Clinical Researchers	Researchers	Murdoch Children's Research Institute	Significance of low-level mosaicism to intellectual disability in paediatric disorders	Awarded - Executed	\$476,728	\$0	\$59,591	\$119,182	\$119,182	\$119,182	\$59,591	\$0	\$0
Clinical Researchers	Researchers	Queensland University of Technology	Embracing digital disruption in hospitals to improve outcomes among vulnerable people	Awarded - Executed	\$483,404	\$0	\$0	\$60,426	\$120,851	\$120,851	\$120,851	\$60,426	\$0
Clinical Researchers	Researchers	Sydney Local Health District	Implementing fasting guidelines within an acute hospital surgical setting.	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	The University of Queensland	Early diagnosis and treatment of lung cancer	Awarded - Executed	\$487,893	\$0	\$0	\$48,789	\$97,579	\$97,579	\$97,579	\$97,579	\$48,789
Clinical Researchers	Researchers	The University of Queensland	iAx: Instant assessment and personalised feedback in alcohol use disorder	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	The University of Queensland	Improving paediatric critical care outcome	Awarded - Executed	\$348,495	\$0	\$0	\$34,850	\$69,699	\$69,699	\$69,699	\$69,699	\$34,850
Clinical Researchers	Researchers	The University of Queensland	Personalised early detection of melanoma	Awarded - Executed	\$577,189	\$0	\$57,719	\$115,438	\$115,438	\$115,438	\$115,438	\$57,719	\$0
Clinical Researchers	Researchers	The University of Queensland	Scaling, spreading, and sustaining The Systematised, Interdisciplinary Malnutrition Program for implementation and Evaluation (SIMPLE) – a multi-site implementation program	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0

Clinical Researchers	Researchers	University of Melbourne	Closing the communication gap in chronic disease	Awarded - Executed	\$179,118	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	University of Melbourne	Complex depression and anxiety in youth: Innovative e-therapy and biotherapy clinical trials	Awarded - Executed	\$349,629	\$0	\$0	\$43,704	\$87,407	\$87,407	\$87,407	\$43,704	\$0
Clinical Researchers	Researchers	University of Melbourne	Elimination of Hepatitis C Virus (HCV) as a Public Health Threat	Awarded - Executed	\$481,156	\$0	\$48,116	\$96,231	\$96,231	\$96,231	\$96,231	\$48,116	\$0
Clinical Researchers	Researchers	University of Melbourne	Examining new treatments and developing new treatment biomarkers for youth with severe depression	Awarded - Executed	\$333,710	\$0	\$41,714	\$83,427	\$83,427	\$83,427	\$41,714	\$0	\$0
Clinical Researchers	Researchers	University of Melbourne	From simulation to translation: A new quality improvement program for antibiotic prescribing in general practice	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	University of Melbourne	Neuroimaging in mental health: the quest for clinically useful biomarkers	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0
Clinical Researchers	Researchers	University of Melbourne	Optimising interventions for Staphylococcus aureus and skin infections	Awarded - Executed	\$333,710	\$0	\$41,714	\$83,427	\$83,427	\$83,427	\$41,714	\$0	\$0
Clinical Researchers	Researchers	University of Melbourne	Optimising Respiratory Therapies to Improve Outcomes for Preterm Infants	Awarded - Executed	\$305,925	\$0	\$0	\$38,241	\$76,481	\$76,481	\$76,481	\$38,241	\$0
Clinical Researchers	Researchers	University of Melbourne	Precision therapy for neurological diseases	Awarded - Executed	\$476,728	\$0	\$59,591	\$119,182	\$119,182	\$119,182	\$59,591	\$0	\$0
Clinical Researchers	Researchers	University of New South Wales	Catch them when they fall: Providing best evidence care after a suicide attempt	Awarded - Executed	\$179,118	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	University of New South Wales	Determinants of the outcomes from infectious diseases	Awarded - Executed	\$577,189	\$0	\$57,719	\$115,438	\$115,438	\$115,438	\$115,438	\$57,719	\$0
Clinical Researchers	Researchers	University of New South Wales	Discovery to therapy implementation in acute stroke	Awarded - Executed	\$577,189	\$0	\$57,719	\$115,438	\$115,438	\$115,438	\$115,438	\$57,719	\$0
Clinical Researchers	Researchers	University of New South Wales	Improving internet-delivered psychological therapies for depression and anxiety	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0

Clinical Researchers	Researchers	University of New South Wales	Reducing the burden of dialysis catheter complications - a national approach	Awarded - Executed	\$179,118	\$0	\$22,390	\$89,559	\$67,169	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	University of New South Wales	Sepsis Outcomes Research	Awarded - Executed	\$278,795	\$0	\$27,880	\$55,759	\$55,759	\$55,759	\$55,759	\$27,880	\$0
Clinical Researchers	Researchers	University of New South Wales	Understanding and optimising the delivery of chronic disease care for better cardiovascular outcomes	Awarded - Executed	\$476,728	\$0	\$59,591	\$119,182	\$119,182	\$119,182	\$59,591	\$0	\$0
Clinical Researchers	Researchers	University of Sydney	Clinical Trials To Improve Outcome of Cancer Patients	Awarded - Executed	\$483,404	\$0	\$0	\$60,426	\$120,851	\$120,851	\$120,851	\$60,426	\$0
Clinical Researchers	Researchers	University of Sydney	Decreasing unnecessary surgery for low back pain	Awarded - Executed	\$476,728	\$0	\$59,591	\$119,182	\$119,182	\$119,182	\$59,591	\$0	\$0
Clinical Researchers	Researchers	University of Sydney	Improving diagnosis, treatment and prevention of mitochondrial disease	Awarded - Executed	\$481,156	\$0	\$0	\$48,116	\$96,231	\$96,231	\$96,231	\$96,231	\$48,116
Clinical Researchers	Researchers	University of Sydney	Improving health outcomes for disadvantaged children	Awarded - Executed	\$577,189	\$0	\$57,719	\$115,438	\$115,438	\$115,438	\$115,438	\$57,719	\$0
Clinical Researchers	Researchers	University of Sydney	New approaches for treatment of alcohol use disorder	Awarded - Executed	\$418,050	\$0	\$0	\$41,805	\$83,610	\$83,610	\$83,610	\$83,610	\$41,805
Clinical Researchers	Researchers	University of Sydney	The role of cortical dysfunction in Amyotrophic Lateral Sclerosis (ALS) pathophysiology	Awarded - Executed	\$585,270	\$0	\$0	\$58,527	\$117,054	\$117,054	\$117,054	\$117,054	\$58,527
Clinical Researchers	Researchers	University of Sydney	Vaccine safety research in understudied and at risk groups: critical knowledge to inform practice and policy	Awarded - Executed	\$286,037	\$0	\$35,755	\$71,509	\$71,509	\$71,509	\$35,755	\$0	\$0
Clinical Researchers	Researchers	University of Tasmania	Exercise is medicine so why don't General Practitioners prescribe it?	Awarded - Executed	\$181,066	\$0	\$0	\$45,267	\$90,533	\$45,267	\$0	\$0	\$0
Clinical Researchers	Researchers	University of Tasmania	Improving musculoskeletal pain by matching the right treatment with the right patient	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0
Clinical Researchers	Researchers	University of Tasmania	Sustaining oral and systemic health in Residential Aged Care Facilities	Awarded - Executed	\$179,118	\$0	\$44,780	\$89,559	\$44,780	\$0	\$0	\$0	\$0

Clinical Researchers	Researchers	University of Western Australia	Community-based studies of diabetes and infectious diseases	Awarded - Executed	\$585,270	\$0	\$0	\$58,527	\$117,054	\$117,054	\$117,054	\$117,054	\$58,527
Clinical Researchers	Researchers	University of Western Australia	Developing personalised treatment for retinal degeneration	Awarded - Executed	\$258,600	\$0	\$32,325	\$64,650	\$64,650	\$64,650	\$32,325	\$0	\$0
Clinical Researchers	Researchers	University of Western Australia	Maximising health for older Australians	Awarded - Executed	\$585,270	\$0	\$0	\$58,527	\$117,054	\$117,054	\$117,054	\$117,054	\$58,527
Clinical Researchers	Researchers	University of Western Australia	Nutritional strategies for allergy prevention	Awarded - Executed	\$431,000	\$0	\$53,875	\$107,750	\$107,750	\$107,750	\$53,875	\$0	\$0
Clinical Researchers	Researchers	University of Western Australia	Translational Research on Malignant Pleural Effusion and Pleural Infection	Awarded - Executed	\$481,156	\$0	\$48,116	\$96,231	\$96,231	\$96,231	\$96,231	\$48,116	\$0
Clinical Researchers	Researchers	University of Wollongong	Implementing a health literacy focused dietetic outpatient model of care for people with chronic kidney disease	Awarded - Executed	\$179,118	\$0	\$29,853	\$89,559	\$59,706	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	Walter and Eliza Hall Institute of Medical Research	Translational research to drive improved diagnosis and treatment of inflammatory diseases	Awarded - Executed	\$418,050	\$0	\$0	\$41,805	\$83,610	\$83,610	\$83,610	\$83,610	\$41,805
Clinical Researchers	Researchers	University of Newcastle	Translation of preventive care for chronic disease risk behaviours into community mental health service delivery	Awarded - Executed - later relinquished	\$179,118	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	Western Sydney Local Health District	Role of Non-Invasive Imaging using Speckle Tracking Echocardiography in the Identification and Treatment of Patients At Risk of Arrhythmias and Consequent Sudden Cardiac Arrest	Awarded - Executed - later relinquished	\$431,000	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	University of New South Wales	Pragmatic implementation trial to reduce evidence practice gap in chronic kidney disease and diabetes	Awarded - Executed - later relinquished	\$179,118	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Clinical Researchers	Researchers	Monash University	Closing the evidence-practice gap with a highly innovative, patient-centred, decision-support program to guide narcotic use in chronic low back pain	Awarded - Executed - later relinquished	\$179,118	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0

Clinical Researchers	Researchers	La Trobe University	Development and implementation of evidence-based stroke rehabilitation	Awarded - Executed - later relinquished	\$483,404	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Clinical Researcher	Researchers	Baker Heart and Diabetes Institute	Utility of novel exercise imaging to identify sub-clinical cardiovascular disease	Awarded - Executed - later relinquished	\$483,404	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Australian Lung Health Initiative Pty Ltd	4D Functional diagnosis: a new frontier in lung health for children	Awarded - Executed	\$960,000	\$0	\$0	\$0	\$960,000	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Burnet Institute	EVE-M (Enhancing the Vaginal Environment and Microbiome) Initiative	Awarded - Executed	\$895,346	\$0	\$0	\$0	\$895,346	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Florey Institute of Neuro-science and Mental Health	Precision Medicine in Epilepsy	Awarded - Executed	\$999,956	\$0	\$0	\$0	\$999,956	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Monash University	An Innovative Public Health Program Against Mosquito-Borne Diseases	Awarded - Executed	\$964,700	\$0	\$0	\$0	\$964,700	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Monash University	Cortical Frontiers: Commercialising Brain Machine Interfaces	Awarded - Executed	\$924,100	\$0	\$0	\$0	\$924,100	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	SALUDA MEDICAL PTY LIMITED	Cerebral palsy treatment by closed loop electrical stimulation	Awarded - Executed	\$747,596	\$0	\$0	\$0	\$747,596	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	The University of Queensland	Therapeutic Ultrasound for the Treatment of Brain Disorders	Awarded - Executed	\$1,000,000	\$0	\$0	\$0	\$1,000,000	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	University of Melbourne	Using disruptive technologies to transform prehospital care for stroke	Awarded - Executed	\$1,000,000	\$0	\$0	\$0	\$1,000,000	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	University of Technology Sydney	Disruptive technologies to trace, track & tackle antibiotic resistance	Awarded - Executed	\$998,731	\$0	\$0	\$0	\$998,731	\$0	\$0	\$0	\$0
Frontier Health and Medical Research	FHMR Stage One, Rd 1	Walter and Eliza Hall Institute of Medical Research	c-FIND: CRISPR Frontier Infection Diagnostics to Detect Infection	Awarded - Executed	\$1,000,000	\$0	\$0	\$0	\$1,000,000	\$0	\$0	\$0	\$0
Totals					\$35,393,332	\$0	\$1,812,557	\$4,996,658	\$15,507,857	\$5,124,431	\$3,714,150	\$1,862,781	\$439,735

Notes:

Clinical Researchers funding agreements include indexation and a stipend which is calculated separately by NHMRC and is additional to the above funding amounts. While Total funding includes the value of relinquished grant, the sum of funds across financial years does not.

TRANSLATION - Funding Agreements executed as at 30 September 2019

MRFF Initiative	Funding Opportunity	Funded Institution	Project Name	Status	Total Funding	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Medical Research Commercialisation	Biomedical Translation Bridge Program (MTPConnect)	MTP Connect	Biomedical Translation Bridge	Awarded - Executed	\$22,300,000	\$0	\$0	\$10,400,000	\$5,300,000	\$5,300,000	\$1,300,000	\$0	\$0
Medical Research Commercialisation	BioMedTech Horizons Program 1 - Via MTPConnect	MTPConnect	BioMedTech Horizons Program (Rd 1)	Awarded - Executed	\$10,000,000	\$0	\$10,000,000	\$0	\$0	\$0	\$0	\$0	\$0
Medical Research Commercialisation	BioMedTech Horizons Program 2 & 3 - Via MTPConnect	MTPConnect	BioMedTech Horizons Program (Rd 2 & 3)	Awarded - Executed	\$35,000,000	\$0	\$0	\$5,000,000	\$10,000,000	\$20,000,000	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - targeted grant opportunity	University of Canberra	Environmental and social determinants of health in the Australian Capital Territory: program interventions aimed at reducing the burden of disease and avoidable hospital admissions.	Awarded - Executed	\$4,000,000	\$0	\$0	\$4,000,000	\$0	\$0	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - targeted grant opportunity	University of Tasmania	Risk Reduction for Dementia Intervention– North West (RREDI-NOW) - an initiative of the Wicking Centre 'Island Study Linking Ageing and Neurodegenerative Disease (ISLAND)' & CAPITOL project	Awarded - Executed	\$2,400,000	\$0	\$0	\$800,000	\$800,000	\$800,000	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Baker Heart and Diabetes Institute	Reduction of Heart Failure Readmission in Resource-Constrained Environments: Supporting Nurse-led Disease Management by Risk-Guidance and eHealth	Awarded - Executed	\$287,663	\$0	\$0	\$287,663	\$0	\$0	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	La Trobe University	Reducing inappropriate knee joint replacement surgery and hospital burden	Awarded - Executed	\$1,337,750	\$0	\$0	\$447,090	\$499,150	\$391,510	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	La Trobe University	Transforming pulmonary rehabilitation to reduce hospital admissions in COPD	Awarded - Executed	\$1,220,668	\$0	\$0	\$460,930	\$443,918	\$315,820	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Macquarie University	Harnessing implementation science, complexity science and evidence-based care to Keep Australians Out of Hospital: leveraging seven natural experiments in New South Wales	Awarded - Executed	\$1,505,612	\$0	\$0	\$490,204	\$505,204	\$510,204	\$0	\$0	\$0

Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Queensland University of Technology	An early detection program to prevent unnecessary hospital admissions of aged care residents	Awarded - Executed	\$1,898,519	\$0	\$0	\$506,151	\$899,139	\$493,230	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	Queensland University of Technology	LOCAl Assessment and Triage Evaluation of NAFLD (LOCATE-NAFLD)	Awarded - Executed	\$969,193	\$0	\$0	\$235,206	\$381,481	\$352,506	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	The Enhance care study: multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer	Awarded - Executed	\$1,061,522	\$0	\$0	\$270,717	\$344,005	\$446,800	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	The RESilience to Seasonal Illness and Increased Emergency admissioNs CarE (RESILIENCE) Study	Awarded - Executed	\$1,284,327	\$0	\$0	\$462,951	\$451,752	\$369,624	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Melbourne	There's no place like home: national scale up of the paediatric low risk febrile neutropenia program	Awarded - Executed	\$1,237,016	\$0	\$0	\$486,772	\$388,396	\$361,849	\$0	\$0	\$0
Preventative and Public Health Research	Keeping Australians out of Hospital - competitive grant opportunity	University of Technology Sydney	Translation of best practice osteoporosis refracture prevention: stopping fragility fractures to keep Australians out of hospital	Awarded - Executed	\$897,730	\$0	\$0	\$230,291	\$347,216	\$320,223	\$0	\$0	\$0
Preventative and Public Health Research	Targeted Health System and Community Organisation Research	The University of Adelaide	Mobile X-ray services provided within residential aged care facilities	Awarded - Executed	\$1,970,000	\$0	\$0	\$630,000	\$610,000	\$730,000	\$0	\$0	\$0
Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd2	University of Tasmania	ANCHOR Project: heAlth ecoNomics and epidemiology of myalgic encephalomyelitis/chronic fatigue syndrome	Awarded - Executed	\$155,000	\$0	\$0	\$95,000	\$55,000	\$5,000	\$0	\$0	\$0
Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd1	Monash University	Assessing diagnostic accuracy for melanoma with compared to without access to Melanoma Surveillance Photography in high-risk individuals	Awarded - Executed	\$2,416,998	\$0	\$0	\$1,034,528	\$619,528	\$762,942	\$0	\$0	\$0
Preventative and Public Health Research	Targeted Health System and Community Organisation Research Rd1	University of Western Australia	Evaluation of clinical pathways and patient outcomes for breast MRI in preoperative assessment and staging of breast cancer: Establishing when MRI improves patient outcomes and when it does not.	Awarded - Executed	\$2,072,217	\$0	\$0	\$1,003,805	\$752,420	\$315,992	\$0	\$0	\$0

Preventative and Public Health Research	Boosting Preventive Health Research Program Via Sax institute	Sax Institute	The Australian Prevention Partnership Centre (TAPPC)	Awarded - Executed	\$10,000,000	\$10,000,000	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	Monash University Monash Partners	Monash Partners Advanced Health Translation Centre – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,131,439	\$0	\$0	\$0	\$2,065,720	\$2,065,720	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	The University of Queensland Brisbane Diamantina Health Partners	Brisbane Diamantina Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000	\$0	\$0	\$0	\$2,055,000	\$2,055,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Melbourne Melbourne Academic Centre for Health (MACH)	Melbourne Academic Centre for Health – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,431,900	\$0	\$0	\$0	\$2,215,950	\$2,215,950	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Sydney Sydney Health Partners	Sydney Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,118,000	\$0	\$0	\$0	\$2,059,000	\$2,059,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Western Australia WA Health Translation Network (WAHTN)	Western Australian Health Translation Network – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,138,000	\$0	\$0	\$0	\$2,069,000	\$2,069,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of Newcastle NSW Regional Health Partners	NSW Regional Health Partners – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000	\$0	\$0	\$0	\$2,055,000	\$2,055,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	South Australian Health and Medical Research Institute (SAHMRI)	Health Translation SA – MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000	\$0	\$0	\$0	\$2,055,000	\$2,055,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.2	University of NSW The Sydney Partnership for Health, Education and Research Enterprise (SPHERE)	Maridulu Budyari Gumal Sydney Partnership for Health Education Research and Enterprise (SPHERE)– MRFF Rapid Applied Research Translation, Stage Two	Awarded - Executed	\$4,110,000	\$0	\$0	\$0	\$2,055,000	\$2,055,000	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	Monash University	Monash Partners	Awarded - Executed	\$1,978,561	\$0	\$0	\$1,978,561	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	The University of Queensland	Brisbane Diamantina Health Partners	Awarded - Executed	\$2,000,000	\$0	\$0	\$2,000,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Melbourne	Melbourne Academic Centre for Health (MACH)	Awarded - Executed	\$1,678,100	\$0	\$0	\$1,678,100	\$0	\$0	\$0	\$0	\$0

Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Sydney	Sydney Health Partners - Transformative translational research and National system initiatives	Awarded - Executed	\$1,992,000	\$0	\$0	\$1,992,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Western Australia	WA Health Translation Network (WAHTN)	Awarded - Executed	\$1,972,000	\$0	\$0	\$1,972,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	Central Australia Academic Health Science Centre	Central Australian Aboriginal Congress	Awarded - Executed	\$2,000,000	\$0	\$0	\$2,000,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of Newcastle NSW Regional Health Partners	NSW Regional Health Partners	Awarded - Executed	\$2,000,000	\$0	\$0	\$2,000,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	South Australian Health and Medical Research Institute (SAHMRI)	SAHMRI Rapid Applied Research Translation Program	Awarded - Executed	\$2,000,000	\$0	\$0	\$2,000,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 2.1	University of NSW	The Sydney partnership for Health, Education and Research Enterprise (SHERE)	Awarded - Executed	\$2,000,000	\$0	\$0	\$2,000,000	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	Monash University Monash Partners	Monash Partners Rapid Translation Projects - Component A	Awarded - Executed	\$2,222,222	\$0	\$2,222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	The University of Queensland	Brisbane Diamantina Health Partners	Awarded - Executed	\$222,222	\$0	\$222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Melbourne	Melbourne Academic Centre for Health (MACH)	Awarded - Executed	\$2,222,222	\$0	\$2,222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Sydney Sydney Health Partners	Transformative translational research and National system initiatives	Awarded - Executed	\$2,222,222	\$0	\$2,222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Western Australia WA Health Translation Network (WAHTN)	Collaborative research into national system level initiative/s Component B	Awarded - Executed	\$222,222	\$0	\$222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	Central Australia Academic Health Science Centre	Central Australian Aboriginal Congress	Awarded - Executed	\$222,222	\$0	\$222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of Newcastle	NSW Regional Health Partners	Awarded - Executed	\$222,222	\$0	\$222,222	\$0	\$0	\$0	\$0	\$0	\$0
Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	South Australian Health and Medical Research Institute	SAHMRI Rapid Applied Research Translation Program	Awarded - Executed	\$2,222,222	\$0	\$2,222,222	\$0	\$0	\$0	\$0	\$0	\$0

Rapid Applied Research Translation	Rapid Applied Research Translation Program - Round 1	University of NSW	Sydney Partnership for Health Education Research and Enterprise (SPHERE)	Awarded - Executed	\$222,222	\$0	\$222,222	\$0	\$0	\$0	\$0	\$0	\$0
TOTALS					\$162,894,213	\$10,000,000	\$19,999,998	\$44,461,968	\$39,026,878	\$48,105,370	\$1,300,000	\$0	\$0

My Health Record opt-out figures (16 July 2018 - 31 January 2019)

	Opt-out requests	Medicare users (at 31 January 2019)	% of eligible Australians with a record
Opt out period*	2,517,921	25,459,544	90.1 per cent

*The Opt-out period concluded on 31 January 2019.

Following the opt-out period, as at 29 September 2019:

- 23,528 records were cancelled on the request of consumers, since 22 February 2019
- 22,129 people have opted back in, since 22 February 2019
- nine in ten eligible Australians have a My Health Record with approximately 22.61 million (22,613,936) registered.

State: Bulk Billing Rate for GP Non-Referred Attendances

State	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
NSW	86.8%	87.6%	88.2%	88.6%	88.7%	88.9%	88.9%
VIC	82.0%	83.1%	84.0%	84.8%	85.2%	85.4%	85.5%
QLD	81.6%	82.8%	83.7%	84.5%	85.4%	85.9%	86.0%
SA	81.3%	82.3%	83.3%	84.0%	84.8%	84.9%	85.2%
WA	72.9%	75.3%	77.8%	80.1%	82.4%	84.0%	85.3%
TAS	76.1%	77.0%	77.3%	76.7%	76.5%	76.4%	76.4%
NT	77.4%	80.7%	84.5%	87.4%	88.9%	89.7%	89.6%
ACT	54.9%	57.0%	57.9%	60.0%	61.8%	63.0%	64.1%
Australia	82.2%	83.4%	84.3%	85.1%	85.7%	86.1%	86.2%

State: Percentage of Patients with all GP Non-Referred Attendances Bulk Billed

State	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
NSW	68.9%	70.1%	71.0%	71.5%	71.7%	71.8%	71.6%
VIC	60.5%	61.9%	63.2%	64.1%	64.9%	65.1%	65.2%
QLD	59.9%	61.1%	62.2%	63.3%	64.6%	65.1%	65.0%
SA	58.5%	59.3%	60.6%	61.6%	62.7%	62.8%	63.2%
WA	49.0%	51.5%	54.5%	57.6%	60.8%	63.1%	64.9%
TAS	51.2%	51.7%	51.7%	50.6%	50.1%	49.6%	49.3%
NT	59.7%	63.1%	67.9%	71.7%	74.6%	75.8%	76.3%
ACT	31.7%	33.3%	33.9%	35.5%	36.6%	37.8%	39.1%
Australia	61.1%	62.4%	63.7%	64.7%	65.7%	66.1%	66.3%

State: Average Out-of-Pocket Cost for GP Non-Referred Attendances

State	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
NSW	\$ 28.28	\$ 30.12	\$ 31.20	\$ 33.55	\$ 35.09	\$ 36.62	\$ 37.63
VIC	\$ 28.93	\$ 30.55	\$ 31.97	\$ 34.02	\$ 35.67	\$ 37.16	\$ 38.55
QLD	\$ 29.87	\$ 31.46	\$ 32.49	\$ 34.56	\$ 36.23	\$ 38.06	\$ 39.04
SA	\$ 25.51	\$ 26.90	\$ 27.89	\$ 29.69	\$ 31.09	\$ 32.59	\$ 33.49
WA	\$ 31.56	\$ 33.53	\$ 34.61	\$ 36.51	\$ 37.92	\$ 39.22	\$ 39.97
TAS	\$ 29.61	\$ 31.65	\$ 32.54	\$ 34.04	\$ 35.75	\$ 37.50	\$ 38.90
NT	\$ 38.31	\$ 40.08	\$ 41.17	\$ 43.78	\$ 45.03	\$ 46.58	\$ 46.14
ACT	\$ 34.70	\$ 36.18	\$ 37.18	\$ 39.73	\$ 42.19	\$ 44.06	\$ 45.22
Australia	\$ 29.32	\$ 31.03	\$ 32.16	\$ 34.24	\$ 35.83	\$ 37.39	\$ 38.46

State: Bulk Billing Rate for Specialist Attendances

State	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
NSW	33.4%	33.7%	34.5%	34.6%	35.3%	35.6%	36.0%
VIC	28.0%	28.7%	29.5%	29.7%	30.0%	30.2%	30.9%
QLD	23.2%	24.3%	24.9%	25.7%	26.1%	27.1%	26.8%
SA	33.7%	33.6%	34.3%	35.2%	35.1%	34.6%	34.5%
WA	16.5%	16.8%	16.9%	17.4%	19.1%	20.2%	21.9%
TAS	28.9%	29.7%	29.7%	30.1%	30.6%	32.3%	33.4%
NT	47.9%	48.8%	46.0%	46.9%	40.4%	38.9%	38.3%
ACT	23.9%	26.0%	27.3%	27.2%	28.9%	27.8%	28.0%
Australia	28.7%	29.2%	29.9%	30.2%	30.7%	31.1%	31.5%

State: Average Out-of-Pocket Cost for Specialist Attendances

State	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19
NSW	\$ 62.73	\$ 66.79	\$ 71.80	\$ 77.75	\$ 82.26	\$ 87.72	\$ 91.92
VIC	\$ 52.20	\$ 56.10	\$ 60.44	\$ 65.84	\$ 70.23	\$ 74.66	\$ 78.30
QLD	\$ 58.29	\$ 62.37	\$ 66.77	\$ 71.87	\$ 75.29	\$ 80.13	\$ 83.98
SA	\$ 44.75	\$ 47.91	\$ 50.99	\$ 54.83	\$ 58.39	\$ 61.72	\$ 64.73
WA	\$ 56.39	\$ 61.42	\$ 66.81	\$ 72.58	\$ 75.35	\$ 79.18	\$ 82.65
TAS	\$ 44.96	\$ 48.42	\$ 52.80	\$ 57.52	\$ 60.18	\$ 63.26	\$ 66.76
NT	\$ 66.95	\$ 73.42	\$ 80.64	\$ 82.96	\$ 85.89	\$ 89.32	\$ 93.60
ACT	\$ 69.61	\$ 74.42	\$ 80.58	\$ 87.51	\$ 91.68	\$ 98.12	\$ 102.94
Australia	\$ 57.03	\$ 61.11	\$ 65.73	\$ 71.21	\$ 75.22	\$ 79.94	\$ 83.77

Medicines recommended by the PBAC and not yet listed or approved to be listed**Table 1:** current as at 17 October 2019

PBAC Meeting August 2019		
MEDICINE	INDICATION	STATUS
DOLUTEGRAVIR WITH LAMIVUDINE Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg Dovato® ViiV Healthcare Pty Ltd	Human immunodeficiency virus (HIV) infection	Under active negotiation
FERRIC DERISOMALTOSE Injection 1000 mg (iron) in 10 mL Injection 500 mg (iron) in 5 mL Monofer® Pfizer Australia Pty Ltd	Iron deficiency anaemia	Under active negotiation
INFLUENZA QUADRIVALENT ADJUVANTED VACCINE Injection 0.5 mL Fluad® Quad Seqirus (Australia) Pty Ltd	Prevention of seasonal influenza	NIP listing processes are underway
LENALIDOMIDE 5 mg capsule, 14, 21 10 mg capsule, 14, 21 15 mg capsule, 14, 21 25 mg capsule, 14, 21 Revlimid® Celgene Pty Ltd	Multiple myeloma	Under active negotiation

PBAC Meeting July 2019

MEDICINE	INDICATION	STATUS
AFLIBERCEPT Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) pre-filled syringe Eylea® Bayer Australia Ltd	Subfoveal choroidal neovascularisation (CNV)	Under active negotiation
AMINO ACID FORMULA WITH VITAMINS AND MINERALS, LOW PHENYLALANINE WITH DOCOSAHEXAINOIC ACID AND ARACHIDONIC ACID Sachets containing oral powder 12.5 g, 30 (PKU Explore 5) Sachets containing oral powder 25 g, 30 (PKU Explore 10) PKU Explore® Vitaflo Australia Pty Ltd	Phenylketonuria (PKU)	Progressing through listing processes
BLINATUMOMAB Powder for I.V. infusion 38.5 micrograms Blincyto® Amgen Australia Pty Ltd	Acute lymphoblastic leukaemia	Progressing through listing processes

PBAC Meeting July 2019		
MEDICINE	INDICATION	STATUS
<p>CARMELLOSE Eye drops containing carmellose sodium 5 mg per mL, 10 mL Evolve® carmellose</p> <p>HYPROMELLOSE Eye drops containing hypromellose 3 mg per mL, 10 mL Evolve® hypromellose</p> <p>Contact Lens Centre Australia Ltd</p>	Severe dry eye syndrome	Under active negotiation
<p>CINACALCET Tablet 30 mg Tablet 60 mg Tablet 90 mg Pharmacor Cinacalcet® Pharmacor Pty Limited</p>	Chronic kidney disease	No Price package received from sponsor that is consistent with PBAC recommendation.
<p>CLOSTRIDIUM BOTULINUM TYPE A TOXIN-HAEMAGGLUTININ COMPLEX Lyophilised powder for I.M. injection 300 units Lyophilised powder for I.M. injection 500 units Dysport® Ipsen Pty Ltd</p>	Focal spasticity of the lower limb (LLFS)	Under active negotiation
<p>FLUTICASONE FUROATE Powder for oral inhalation in breath actuated device containing fluticasone furoate 50 micrograms per dose, 30 doses Arnuity Ellipta® GlaxoSmithKline Australia Pty Ltd</p>	Asthma	No Price package received from sponsor that is consistent with PBAC recommendation.
<p>GALCANEZUMAB Injection 120 mg in 1 mL single use pre-filled pen Emgality® Eli Lilly Australia Pty Ltd</p>	Chronic migraine	No Price package received from sponsor that is consistent with PBAC recommendation.
<p>GLYCOMACROPEPTIDE AND ESSENTIAL AMINO ACIDS WITH VITAMINS AND MINERALS Sachets containing oral powder 35 g, 30 (TYR Sphere 20) TYR Sphere 20® VitaFlo Australia Pty Ltd</p>	Tyrosinaemia	Progressing through listing processes
<p>GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID WITH LOW PHENYLALANINE Oral liquid 250 mL, 18 PKU GMPro LQ® Nutricia Australia Pty Ltd</p>	Phenylketonuria (PKU)	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting July 2019		
MEDICINE	INDICATION	STATUS
INFLUENZA QUADRIVALENT VACCINE Injection 0.5 mL Vaxigrip Tetra™ Sanofi-Aventis Australia Pty Ltd	Prevention of seasonal influenza	NIP listing processes are underway
LENALIDOMIDE Capsule 5 mg Capsule 10 mg Capsule 15 mg Revlimid® Celgene Pty Ltd	Multiple myeloma (MM)	Under active negotiation
LISDEXAMFETAMINE Capsule containing lisdexamfetamine dimesilate 20 mg Capsule containing lisdexamfetamine dimesilate 40 mg Capsule containing lisdexamfetamine dimesilate 60 mg Vyvanse® Shire Australia Pty Ltd	Attention deficit hyperactivity disorder (ADHD)	No Price package received from sponsor that is consistent with PBAC recommendation.
OCTREOTIDE Injection (modified release) 30 mg (as acetate), vial and diluent syringe Sandostatin® Novartis Pharmaceuticals Australia Pty Ltd	Non-functional neuroendocrine tumours of midgut or suspected midgut origin	Under active negotiation
OXYCODONE Capsule containing oxycodone hydrochloride 5 mg, 10 OxyNorm® Mundipharma Pty Limited	Severe disabling pain	Under active negotiation
PEMBBROLIZUMAB Solution concentrate for I.V. infusion 100 mg in 4 mL Keytruda® Merck Sharp & Dohme (Australia) Pty Ltd	Non-small cell lung cancer	Under active negotiation
RISANKIZUMAB Injection 75 mg in 0.83 mL prefilled syringe Skyrizi® AbbVie Pty Ltd	Chronic plaque psoriasis	Under active negotiation
SAPROPTERIN Powder for oral liquid 100 mg (as dihydrochloride), Powder for oral liquid 500 mg (as dihydrochloride) Tablet (soluble) containing sapropterin dihydrochloride 100 mg Kuvan® BioMarin Pharmaceutical Australia Pty Ltd	Hyperphenylalaninaemia (HPA)	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting July 2019		
MEDICINE	INDICATION	STATUS
SODIUM PHENYLBUTYRATE Granules 483 mg (as sodium) per g, 174 g Pheburane® Orpharma Pty Ltd	Urea cycle disorder (UCD)	Progressing through listing processes
TRASTUZUMAB Powder for I.V. infusion 60 mg Powder for I.V. infusion 150 mg Powder for I.V. infusion 420 mg Kanjinti® Amgen Australia Pty Ltd	Breast cancer Gastric cancer	Progressing through listing processes

PBAC Meeting May 2019		
MEDICINE	INDICATION	STATUS
Biologics for the treatment of severe asthma: BENRALIZUMAB Injection 30 mg in 1 mL (prefilled syringe) Fasenra® AstraZeneca Pty Ltd MEPOLIZUMAB Injection 100 mg, 1 vial Nucala® GlaxoSmithKline Australia Pty Ltd OMALIZUMAB Injection 75 mg/0.5 mL syringe 150 mg/mL syringe Xolair® Novartis Pharmaceuticals Australia Pty Limited	Severe asthma	Under active negotiation
MENINGOCOCCAL VACCINE (conjugate ACWY) 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (13vPCV) 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23vPPV) HAEMOPHILUS INFLUENZAE TYPE B VACCINE (Conjugate Hib)	Meningococcal, pneumococcal and Haemophilus influenzae type b disease	NIP listing processes are underway
MENINGOCOCCAL VACCINE (conjugate ACWY) (all NIP listed brands)	Meningococcal disease	NIP listing processes are underway

PBAC Meeting March 2019		
MEDICINE	INDICATION	STATUS
ALIROCUMAB Injection 75 mg in 1 mL single dose pre-filled pen Injection 150 mg in 1 mL single dose pre-filled pen Praluent® Sanofi-Aventis Australia Pty Ltd	Hypercholesterolaemia	No Price package received from sponsor that is consistent with PBAC recommendation.
BUDESONIDE Capsule (modified release) 3 mg Entocort® Emerge Health Pty Ltd	Mild to moderate Crohn disease	No Price package received from sponsor that is consistent with PBAC recommendation.
CERTOLIZUMAB PEGOL Injection 200mg in 1 mL pre-syringe pen Solution for injection 200 mg in 1 mL pre-filled pen Cimzia® UCB Australia Pty Ltd	Severe chronic plaque psoriasis	Sponsor has made further submission to PBAC
FLUTICASONE FUROATE with UMECLIDINIUM and VILANTEROL Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenate) per dose, 30 doses Trelegy® Ellipta® GlaxoSmithKline Australia Pty Ltd	Chronic Obstructive Pulmonary Disease (COPD)	No Price package received from sponsor that is consistent with PBAC recommendation.
LEVONORGESTREL Intrauterine drug delivery system 19.5 mg Kyleena® Bayer Australia Ltd	Contraception	No Price package received from sponsor that is consistent with PBAC recommendation.
RITUXIMAB Solution for I.V. infusion 100 mg in 10 mL Solution for I.V. infusion 500 mg in 50 mL Truxima® Celltrion Healthcare Australia Pty. Ltd.	Non-Hodgkin lymphoma	No Price package received from sponsor that is consistent with PBAC recommendation.
SEVELAMER Tablet containing sevelamer carbonate 800 mg Sevelamer Dr Reddy's® Dr Reddy's	Hyperphosphataemia	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting March 2019		
MEDICINE	INDICATION	STATUS
TIOTROPIUM Capsule containing powder for oral inhalation 13 microgram (for use in Zonda device) Braltus® TEVA Australia Pty Ltd	Chronic obstructive pulmonary disease (COPD)	Sponsor could not supply
TRASTUZUMAB Powder for I.V. infusion 150 mg Ontruzant® Merck Sharp & Dohme (Australia) Pty Limited	Breast cancer Gastric cancer	No Price package received from sponsor that is consistent with PBAC recommendation.
TRIGLYCERIDES - MEDIUM CHAIN, FORMULA Oral liquid 500mL, 12 (Nutrini Peptisorb) Oral liquid 500 mL, 12 (Nutrini Peptisorb Energy) Nutrini Peptisorb® Nutrini Peptisorb Energy® Nutricia Australia Pty Limited	Dietary management of conditions requiring a source of medium chain triglycerides	Sponsor cannot supply new pack size at this time

PBAC Meeting November 2018		
MEDICINE	INDICATION	STATUS
GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID WITH LOW PHENYLALANINE Sachets containing oral powder 33.3 g, 16 (PKU GMPro) PKU GMPro Nutricia Australia Pty Limited	Phenylketonuria (PKU)	Sponsor could not supply
PEGFILGRASTIM Injection 6 mg in 0.6 mL single use pre-filled syringe Fulphila® Alphapharm Pty Ltd	Chemotherapy-induced neutropenia	Progressing through listing processes

PBAC Meeting March 2018		
MEDICINE	INDICATION	STATUS
RAMUCIRUMAB (Cyramza®) Injection concentrate for I.V. infusion 100 mg in 10 mL Injection concentrate for I.V. infusion 500 mg in 50 mL Eli Lilly Australia Pty Ltd	Advanced gastric or gastro-oesophageal junction adenocarcinomas	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting March 2018		
MEDICINE	INDICATION	STATUS
RANOLAZINE (Ranexa®) Tablet (modified release) 375 mg Tablet (modified release) 500 mg Tablet (modified release) 750 mg A. Menarini Australia Pty Ltd	Stable angina pectoris	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting November 2017		
MEDICINE	INDICATION	STATUS
SEVELAMER Powder for oral liquid 2.4 g (as carbonate) Renvela® Sanofi-Aventis Australia Pty Ltd	Hyperphosphataemia in patients with chronic kidney disease	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC Meeting March 2017		
MEDICINE	INDICATION	STATUS
TENOFOVIR ALAFENAMIDE Tablet 25 mg Vemlidy® Gilead Sciences Pty Ltd	Chronic hepatitis B	No Price package received from sponsor that is consistent with PBAC recommendation.

PBAC meeting July 2016		
ITEM	INDICATION	STATUS
PNEUMOCOCCAL CONJUGATE VACCINE 13-Valent Adsorbed Pre-Filled Syringe, 0.5 mL, Prevenar 13® Pfizer Australia Pty Ltd	Prevention of pneumococcal disease – Aboriginal and Torres Strait Islander adults 50+ and non-Indigenous adults 65+	NIP listing processes are underway

Medicines recommended by the PBAC – sponsors not proceeding with PBS listing

Where the PBAC has rescinded its recommendations in regards to a medicine, these recommendations are no longer included, as the sponsor would require a new PBAC recommendation to proceed to listing on the PBS.

Table 2: Current as of 17 October 2019

PBAC meeting March 2019	
MEDICINE	INDICATION
<p>BUDESONIDE Capsule (modified release) 3 mg Budenofalk® Orphan Australia Pty Ltd</p>	Crohn disease
<p>TOFACITINIB Tablet 5 mg; Tablet 10 mg Xeljanz® Pfizer Australia Pty Ltd</p>	Ulcerative Colitis (UC)
PBAC Meeting November 2018	
MEDICINE	INDICATION
<p>SARILUMAB Injection 200mg in 1.14mL</p>	Rheumatoid arthritis
<p>ENCORAFENIB and BINIMETINIB Encorafenib: capsule 50 mg; capsule 75 mg Binimetinib: tablet 15 mg BRAFTOVI® and MEKTOVI® Pierre Fabre Australia Pty Ltd</p>	Melanoma
PBAC Meeting July 2018	
MEDICINE	INDICATION
<p>ADALIMUMAB Injection 20 mg in 0.2 mL pre-filled syringe Injection 80 mg in 0.8 mL pre-filled pen Humira® AbbVie Pty Ltd</p>	<p>Severe active rheumatoid arthritis; Sever psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Sever active juvenile idiopathic arthritis; Sever Crohn disease; Refractory fistulating Crohn disease; Moderate to severe ulcerative colitis; Moderate to severe hidradenitis suppurativa</p>
<p>ADALIMUMAB Injection 20mg in 0.4mL pre-filled syringe, Injection 40mg in 0.8mL pre-filled syringe, Injection 40mg in 0.8mL pre-filled pen Amgevita® Amgen Australia</p>	<p>Severe active rheumatoid arthritis; Sever psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Sever active juvenile idiopathic arthritis; Sever Crohn disease; Refractory fistulating Crohn disease; Moderate to severe ulcerative colitis; Moderate to severe hidradenitis suppurativa</p>
<p>ADALIMUMAB Injection 40mg in 0.8mL pre-filled syringe, Injection 40mg in 0.8mL single dose autoinjector Hadlima® MSD Australia</p>	Severe active rheumatoid arthritis

<p>ARIPRAZOLE Powder for injection 400 mg (as monohydrate) with diluent, pre-filled syringe Abilify Maintena® Lundbeck Australia Pty Ltd</p>	<p>Schizophrenia</p>
<p>BUDESONIDE Capsule (modified release) 3 mg Entocort® Emerge Health Pty Ltd</p>	<p>Mild to moderate Crohn disease</p>
<p>MENINGOCOCCAL POLYSACCHARIDE SERO (GROUPS A, C, W-135 AND Y) OLIGOSACCHARIDE CONJUGATE VACCINE Injection 0.5mL combination pack Menveo® GlaxoSmithKline Australia Pty Ltd</p>	<p>Meningococcal disease</p>
<p>PBAC meeting March 2018</p>	
<p>ITEM</p>	<p>INDICATION</p>
<p>CETUXIMAB (Erbix®) Solution for I.V. infusion 100 mg in 20 mL Solution for I.V. infusion 500 mg in 100 mL Merck Serono Australia Pty Ltd</p>	<p>Recurrent or metastatic squamous cell carcinoma of the head and neck</p>
<p>OMALIZUMAB (Xolair®) Injection 150 mg in 1 mL single dose pre-filled syringe Novartis Pharmaceuticals Australia Pty Ltd</p>	<p>Severe chronic spontaneous urticaria</p>
<p>TENECTEPLASE (Metalyse®)</p>	<p>Acute myocardial infarction</p>
<p>PBAC meeting December 2017</p>	
<p>ITEM</p>	<p>INDICATION</p>
<p>ADALIMUMAB Injection 40 mg in 0.4 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled pen Humira® AbbVie Pty Ltd</p>	<p>Severe active rheumatoid arthritis; Sever psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Sever active juvenile idiopathic arthritis; Sever Crohn disease; Refractory fistulating Crohn disease; Moderate to severe ulcerative colitis; Moderate to severe hidradenitis suppurativa</p>
<p>PBAC meeting November 2017</p>	
<p>ITEM</p>	<p>INDICATION</p>
<p>CANAKINUMAB Powder for injection 150 mg with solvent Solution for injection 150mg in 1 mL Ilaris® Novartis Pharmaceuticals Australia Pty Ltd</p>	<p>Cryopyrin associated periodic syndromes (CAPS)</p>
<p>RADIUM (223Ra) Injection containing radium (223Ra) dichloride 6.6 MBq in 6 mL vial Xofigo® Bayer Australia Ltd</p>	<p>Metastatic castrate resistant prostate cancer (mCRPC)</p>

PBAC meeting July 2017	
ITEM	INDICATION
ADALIMUMAB Injection 40 mg in 0.8 mL vial Humira® AbbVie Pty Ltd	New 40 mg vial form recommended to list with the same indications and listings as for the currently listed forms of adalimumab (cartridge and syringe forms).
PBAC meeting March 2017	
ITEM	INDICATION
RITUXIMAB Solution for subcutaneous injection 1600 mg in 13.4 mL MabThera SC® Roche Products Pty Ltd	Chronic lymphocytic leukaemia (CLL)
PBAC meeting November 2016	
ITEM	INDICATION
PARITAPREVIR WITH RITONAVIR WITH OMBITASVIR Tablet containing 75 mg paritaprevir with 50 mg ritonavir with 12.5 mg ombitasvir Technivie® AbbVie Pty Ltd	Hepatitis C
ADRENALINE Tablet containing 75 mg paritaprevir with 50 mg ritonavir with 12.5 mg ombitasvir Technivie® AbbVie Pty Ltd	Anaphylaxis
PBAC meeting July 2016	
ITEM	INDICATION
ADRENALINE Adrenaline Auto Inject Sun-JV® Ranbaxy Australia (Sun Pharma)	Anaphylaxis
ALENDRONIC ACID Tablet, effervescent, 70 mg, Binosto® My Health 365 Pty Ltd New effervescent form for osteoporosis	Osteoporosis
DENOSUMAB Injection 120 mg in 1.7mL, Xgeva® Amgen Australia Pty Ltd	Hypercalcaemia of malignancy
PBAC meeting March 2016	
ITEM	INDICATION
TRIGLYCERIDES MEDIUM CHAIN oral liquid, 12 x 500 mL pouches Peptamen Junior Liquid® Peptamen Junior Advance® Nestlé Health Science (Nestlé Australia Ltd)	For dietary management of conditions requiring a source of medium chain triglycerides limited to fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders
PBAC meeting November 2015	
ITEM	INDICATION
THYROXINE 25, 50, 75, 100, 125, and 200 microgram tablets, 200 Eltroxin® Aspen Pharmacare Australia Pty Ltd	Thyroid hormone deficiency
FLUTICASONE FUROATE 100 microgram/actuation inhalation: powder for, 30 actuations; 200 microgram/actuation inhalation: powder for, 30 actuations Arnuity® Ellipta® GlaxoSmithKline Australia Pty Ltd	Asthma

HPV types 16 and 18 Cervarix® GlaxoSmithKline Australia Pty Ltd	For Human papillomavirus (HPV) Vaccine (Cervarix) for the vaccination of a female who is at least 12 years old but less than 14 years of age to be changed from three doses to two doses.
PBAC meeting July 2015	
ITEM	INDICATION
DEFERASIROX 125, 250, 500 mg tablet Exjade® Novartis Pharmaceuticals Australia Pty Ltd	Include the following populations: - patients with transfusion dependent non-malignant disorders of erythropoiesis; - patients with NTDT; and - patients with transfusion dependent malignant disorders of haemopoiesis with a median life expectancy greater than five years.
EXENATIDE 2 mg injection Bydureon® Astrazeneca Pty Ltd	Diabetes
PNEUMOCOCCAL CONJUGATE VACCINE (13-valent) Prevenar 13® Pfizer Australia Pty Ltd	Prevention of pneumococcal pneumonia and IPD in adults
PBAC meeting March 2015	
ITEM	INDICATION
CANAKINUMAB 150 mg injection Illaris® Novartis Pharmaceutical Australia Pty Ltd	Treatment of systemic juvenile idiopathic arthritis in patients meeting certain criteria
INSULIN GLARGINE 100 IU/mL injection Basaglar®, Basaglar KwikPen® Eli Lilly Australia Pty Ltd	Treatment of type 1 and 2 diabetes mellitus
PROPRANOLOL 3.75 mg/mL oral liquid Hemangiol® Pierre Fabre Australia Pty Ltd	Authority Required (telephone) item on the general schedule for the treatment of proliferating infantile haemangioma requiring systemic therapy.
PBAC meeting November 2014	
ITEM	INDICATION
BUPRENORPHINE AND NALOXONE 4 mg/1 mg film: sublingual, 28 films 12 mg/3 mg film: sublingual, 28 films Suboxone® Sublingual film Reckitt Benckiser Pty Ltd	Opiate dependence
PBAC meeting July 2014	
ITEM	INDICATION
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM collagenase clostridium histolyticum 900 microgram injection [1 x 900 microgram vial] (&) inert substance [1 x 3 mL vial] Xiaflex® Actelion Pharmaceuticals Australia Pty Ltd	Treatment of Dupuytren's contracture in patients meeting certain criteria, on a cost analysis basis that assumes equivalent overall treatment costs between and surgical fasciectomy, but accounting for a lower treatment success rate with CCH compared to surgical fasciectomy as well as higher retreatment and recurrent contracture rates for patients treated with CCH compared to surgical fasciectomy.

PBAC meeting March 2014	
ITEM	INDICATION
LEVONORGESTREL 13.5 mg drug delivery system: intrauterine, 1 Jaydess®, Bayer Australia Ltd	Contraception